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Objectives: Several cross-sectional studies suggest that psychosocial factors are associated 
with non-adherence to chronic preventive maintenance medication (CPMM); however, results 
from longitudinal associations have not yet been systematically summarized. Therefore, the 
objective of this study was to systematically synthesize evidence of longitudinal associations 
between psychosocial predictors and CPMM non-adherence.
Materials and methods: PUBMED, EMBASE, CINAHL, and PsychINFO databases were 
searched for studies meeting our inclusion criteria. The reference lists and the ISI Web of Knowl-
edge of the included studies were checked. Studies were included if they had an English abstract, 
involved adult populations using CPMM living in Western countries, and if they investigated 
associations between psychosocial predictors and medication non-adherence using longitudinal 
designs. Data were extracted according to a literature-based extraction form. Study quality was 
independently judged by two researchers using a framework comprising six bias domains. Studies 
were considered to be of high quality if $four domains were free of bias. Psychosocial predictors 
for non-adherence were categorized into five pre-defined categories: beliefs/cognitions; coping 
styles; social influences and social support; personality traits; and psychosocial well-being. 
A qualitative best evidence synthesis was performed to synthesize evidence of longitudinal 
associations between psychosocial predictors and CPMM non-adherence.
Results: Of 4,732 initially-identified studies, 30 (low-quality) studies were included in the 
systematic review. The qualitative best evidence synthesis demonstrated limited evidence for 
absence of a longitudinal association between CPMM non-adherence and the psychosocial 
categories. The strength of evidence for the review’s findings is limited by the low quality of 
included studies.
Conclusion: The results do not provide psychosocial targets for the development of new 
interventions in clinical practice. This review clearly demonstrates the need for high-quality, 
longitudinal research to identify psychosocial predictors of medication non-adherence.
Keywords: medication adherence, psychosocial factors, systematic review, longitudinal 
 studies, somatic and chronic diseases
Introduction
In conditions such as rheumatoid arthritis, diabetes, and hypertension, long-term 
therapy with chronic preventive maintenance medication (CPMM) is essential for 
reducing risks of disease progression, comorbidity, and mortality. However, sufficient 
medication adherence to CPMM is a prerequisite for reducing these risks.1
Medication non-adherence, or the extent to which patients do not take their medica-
tions as agreed with their health care provider, averages 50% among patients suffering 
from chronic diseases in developed countries.2 Non-adherence can result in poorer 
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health outcomes and a lower quality of life in patients.3 For 
example, patients who did not adhere to beta-blocker therapy 
were four and a half times more likely to have complica-
tions from coronary heart disease than those who adhered to 
therapy.4 Non-adherence also affects health care utilization. 
For instance, poorer adherence among elderly patients with 
moderate-to-severe asthma was associated with a 5% increase 
in annual physician visits, whereas better adherence was 
associated with a 20% decrease in annual hospitalization.5
Considering the undesired consequences of non-adherence 
to CPMM, interventions are needed to improve medication 
non-adherence. According to the World Health Organization 
(WHO), possible targets for these interventions can be divided 
into five domains:2 socio-economic factors, health care system 
factors, condition-related factors, therapy-related factors, 
and patient-related factors. Although none of the factors 
within these domains are consistently associated with non-
adherence across conditions, some tend to be better predictors 
of non-adherence than others (like poverty, the nature of the 
disease, and side-effects).1,2 Also, psychosocial factors like 
beliefs about medication, self-efficacy, and social support can 
be promising intervention targets. These are mostly modifi-
able (in contrast to factors like poverty or side-effects), and 
according to reviews of cross-sectional studies, they appear 
to be associated with non-adherence in various somatic, 
chronic conditions.6–13 Beliefs about medication were the most 
powerful predictors of adherence (among demographic and 
medical factors) in one cross-sectional study,9 while another 
cross-sectional study identified low-self-efficacy as a signifi-
cant predictor of non-adherence across different countries, 
for example.11 However, there is no insight into psychosocial 
factors predicting non-adherence in longitudinal studies with a 
longer follow-up period ($3 months). Such knowledge would 
be helpful in designing effective adherence interventions in 
clinical practice.
This is the first review which aims to systematically 
synthesize evidence of longitudinal associations between psy-
chosocial predictors and CPMM non-adherence across adult 
patients living in Western countries. Since non- adherence 
literature is scattered across diseases,14 we combined stud-
ies from various somatic, chronic conditions to increase the 
robustness of our findings.
Methods
PRISMA-guidelines were followed in performing this 
systematic review.15 The steps taken regarding data searches, 
study selection, data extraction, study quality assessment, data 
synthesis, and data analyses are elaborated below.
Data sources and searches
In March 2011, according to a pre-defined search strategy, 
four electronic databases (PUBMED, EMBASE, CINAHL, 
and PsychINFO) were searched for studies up to February 
2011. With this search, a first set of studies was included, the 
reference lists of these studies were hand searched to find 
additional studies. The studies were also entered into the ISI 
Web of Knowledge citation index (August 2011). The result-
ing list of studies, citing one of the initial included studies in 
our review, was also searched.
The search strategy (see Supplementary Materials) 
 contains key words on medication adherence, chronic, 
somatic diseases, adults, longitudinal designs, and Western 
countries. Countries in Africa, Latin-America, South-
America, Asia (excluding Indonesia and Japan), and Turkey 
were considered as non-Western according to Statistics 
Netherlands.16 Non-Western countries were excluded because 
underlying mechanisms of medication non-adherence could 
differ from those in Western countries due to socio-economic 
and cultural differences.17
In this review, we focused on two of the three components 
of adherence (ie, on initiation and implementation adherence, 
thus the extent to which a patient’s actual medication dosing 
regimen corresponds with the prescribed dosing regimen 
from initiation to last dose). We did not include discontinu-
ation of medication.1
As using CPMM terms in the search strategy was unfea-
sible, we used the corresponding diseases for which the 
CPMMs were prescribed as search terms instead. The disease 
terms were selected as follows:
1. Chronic preventive maintenance medications were 
defined. CPMMs were regarded as drugs that 1) are 
intended to be used chronically to prevent the occurrence 
or worsening of a disease or its complications; and 2) may 
have an immediate effect, but must also have a long-term 
effect (.3 months).
2. From the full November 2010 Anatomical Therapeutic 
Chemical Classification System (ATC)-7 medication 
list of drugs available in the Netherlands, 246 CPMMs 
(Supplementary Materials) were independently selected 
by two pharmacists (BvdB and VH). There was an ini-
tial agreement of 96% on medications being CPMM. 
Disagreements were resolved by discussion between the 
pharmacists.
3. Disease indications for the 246 CPMMs were subse-
quently clustered by BvdB according to the International 
Classification of Diseases (WHO). Finally, 20 disease 
terms were used in the search strategy.
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Table 2 Study characteristics and results*
First author Setting Sample characteristics Measures and results
Sample size,  
% loss to follow-up
Age†, % female Disease duration† Adherence‡, follow-up period§ Psychosocial category,  
number of predictors||
Association present between category  
and adherence/non-adherence?¶
Number domains 
bias free**
Asthma (inhaled corticosteroids)
Ponieman33 USA; patients from general  
internal medicine clinic
261, 23% 48 (13), 82% Age of onset #20  
years: 50% of sample
Self-report (MARS), 3 months Ai, n=5
Aiii, n=3
No (U: yes, M: no)
No (U: no, M: no)
0 of 6
Diabetes (oral and/or parenteral antidiabetics)
venturini34,†† USA; patients from HMO- 
providing health services
786, 0% 59 (mean), 24–92 (range), 49% NR Record review, last time point flexible,  
but within 24 months
ei, n=1 No (U: NR, M: no) 2 of 6
Heart disease and hypertension (cardiovascular medication)
Gazmararian35 USA; community-dwelling  
patients‡‡
1,549, UD Age: 65–69: 35%, 70–74: 28%,  
75–79: 20%, 80–84: 12%, .84:  
6%, (female): 58%
UD Record review, 12 months Ciii, n=1 No (U: no, M: NT) 3 of 6
Nabi26 Finland; local government  
employees
1,021, UD 26–63 (range), 32% 0–2 years: n=311  
2–5 years: n=222  
5–10 years: n=292  
.10 years: n=196
Record review, 12 months D, n=4
ei, n=2
Yes (U: no, M: yes)
No (U: no, M: NT)
1 of 6
Grégoire36 Canada; hypertensive adults with  
prescriptions from network  
of pharmacies
692, 26% 59 (13), 56% 47 months  
(adherent group),  
44 months (non- 
adherent group)
Self-report (Morisky scale), 3 months Ai, n=1
Aii, n=5
Ciii, n=1
No (U: no, M: no)
No (U: no, M: no)
No (U: no, M: no)
0 of 6
Miller37 Site not reported: patients from  
institutions providing cardiac  
rehabilitation programs¶¶
141, 21% 56 (mean), 32–70 (range), 22% NR Self-report (HBS), 6–9 months Ai, n=1
Cii, n=1
No (U: NR, M: no)
No (U: NR, M: no)
0 of 6
Molloy38 UK; patients admitted to hospitals  
with acute coronary syndrome¶¶
295, 11% 61 (mean), 32–87 (range), 23% 0 years (acute) Self-report, 12 months Ciii, n=2 No (U: no, M: no) 1 of 6
HIV (antiretroviral medication)
Deschamps25 Belgium; outpatients at university  
hospital
60, 28% 43 (9) adherent group,  
41 (8) non-adherent group, 16%
NR MeMS, 5–6 months after measuring  
psychosocial constructs
Ai, n=3
Aiii, n=1
Bi, n=3
Bii, n=4
Ciii, n=2
D, n=1
ei, n=2
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
1 of 6
Holmes19 USA; Hiv-clinic patients 116, 0%§§ 44 (median),  
25–69 (range), 19%
5 years (median) MeMS, 12 months (or when viral load  
of $1,000 copies/mL was reached)
Ai, n=1
Aii, n=2
Ci, n=1
Ciii, n=1
ei, n=1
eii, n=1
No (U: no, M: no)
No (U: no, M: no)
No (U: no, M: NT)
No (U: no, M: NT)
No (U: no, M: no)
No (U: no, M: no)
2 of 6
Delgado39 Canada; patients enrolled  
in community drug treatment  
program
316, 0% NR, NR NR Record review, 12 months ei, n=1 No (U: yes, M: no) 1 of 6
Singh40 USA; new, veteran patients seen  
at medical center
52, 12% 40 (median),  
23–68 (range), 0%
NR Record review, 6 months Bii, n=1
Ciii, n=2
ei, n=4
No (U: no, M: no)
No (U: no, M: no)
No (U: no, M: no)
1 of 6
Singh41 Site not reported: patients  
in Hiv-medical centers
138, 11% 41 (median),  
24–71 (range), 7%
NR (but 7%  
therapy-naive)
Record review, 6 months Bi, n=3
Bii, n=6
Ciii, n=4
ei, n=1
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
1 of 6
Bottonari42 USA; patients treated in  
immunodeficiency clinic
78, 69% 36 (7), 4% NR Self-report (straightforward), 6–9 months D, n=2
ei, n=1
eii, n=3
No (U: no, M: NR)
No: (U: no, M: NR)
No: (U: no, M: NR)
0 of 6
Godin43 Canada; patients from medical  
Hiv-clinics
400, 6% 43 (8), 4% .5 years Hiv- 
infected: 73%
Self-report (straightforward), 12 months Ai, n=1
Aiii, n=2
Ci, n=1
Ciii, n=1
D, n=1
Yes (U: NR, M: yes)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
1 of 6
(Continued)
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Heart disease and hypertension (cardiovascular medication)
Gazmararian35 USA; community-dwelling  
patients‡‡
1,549, UD Age: 65–69: 35%, 70–74: 28%,  
75–79: 20%, 80–84: 12%, .84:  
6%, (female): 58%
UD Record review, 12 months Ciii, n=1 No (U: no, M: NT) 3 of 6
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1,021, UD 26–63 (range), 32% 0–2 years: n=311  
2–5 years: n=222  
5–10 years: n=292  
.10 years: n=196
Record review, 12 months D, n=4
ei, n=2
Yes (U: no, M: yes)
No (U: no, M: NT)
1 of 6
Grégoire36 Canada; hypertensive adults with  
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of pharmacies
692, 26% 59 (13), 56% 47 months  
(adherent group),  
44 months (non- 
adherent group)
Self-report (Morisky scale), 3 months Ai, n=1
Aii, n=5
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No (U: no, M: no)
No (U: no, M: no)
No (U: no, M: no)
0 of 6
Miller37 Site not reported: patients from  
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141, 21% 56 (mean), 32–70 (range), 22% NR Self-report (HBS), 6–9 months Ai, n=1
Cii, n=1
No (U: NR, M: no)
No (U: NR, M: no)
0 of 6
Molloy38 UK; patients admitted to hospitals  
with acute coronary syndrome¶¶
295, 11% 61 (mean), 32–87 (range), 23% 0 years (acute) Self-report, 12 months Ciii, n=2 No (U: no, M: no) 1 of 6
HIV (antiretroviral medication)
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No (U: no, M: NR)
1 of 6
Holmes19 USA; Hiv-clinic patients 116, 0%§§ 44 (median),  
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of $1,000 copies/mL was reached)
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Aii, n=2
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Ciii, n=1
ei, n=1
eii, n=1
No (U: no, M: no)
No (U: no, M: no)
No (U: no, M: NT)
No (U: no, M: NT)
No (U: no, M: no)
No (U: no, M: no)
2 of 6
Delgado39 Canada; patients enrolled  
in community drug treatment  
program
316, 0% NR, NR NR Record review, 12 months ei, n=1 No (U: yes, M: no) 1 of 6
Singh40 USA; new, veteran patients seen  
at medical center
52, 12% 40 (median),  
23–68 (range), 0%
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Ciii, n=2
ei, n=4
No (U: no, M: no)
No (U: no, M: no)
No (U: no, M: no)
1 of 6
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Bii, n=6
Ciii, n=4
ei, n=1
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
1 of 6
Bottonari42 USA; patients treated in  
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78, 69% 36 (7), 4% NR Self-report (straightforward), 6–9 months D, n=2
ei, n=1
eii, n=3
No (U: no, M: NR)
No: (U: no, M: NR)
No: (U: no, M: NR)
0 of 6
Godin43 Canada; patients from medical  
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400, 6% 43 (8), 4% .5 years Hiv- 
infected: 73%
Self-report (straightforward), 12 months Ai, n=1
Aiii, n=2
Ci, n=1
Ciii, n=1
D, n=1
Yes (U: NR, M: yes)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
1 of 6
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Table 2 (Continued)
First author Setting Sample characteristics Measures and results
Sample size,  
% loss to follow-up
Age†, % female Disease duration† Adherence‡, follow-up period§ Psychosocial category,  
number of predictors||
Association present between category  
and adherence/non-adherence?¶
Number domains 
bias free**
Kacanek44 USA; patients recruited by  
media and physician networks
225, 0% 45 (7), 23% NR Self-report (straightforward); maximum  
30 months
ei, n=1 Yes (U: yes, M: NT) 2 of 6
Martini45 italy; outpatients using  
combination therapy¶¶
214, 71% ,30: 13%, 30–39: 56%,  
.39: 31%, (female): 36%
NR Self-report (straightforward); 12 months Ai, n=2
Ci, n=1
No (U: no, M: NR)
Yes (U: yes, M: NR)
0 of 6
Mellins46 USA; Hiv-infected mothers  
recruited in waiting room  
of adult clinic
128, 25% 38 (mean),  
22–66 (range), 100%
5 years Self-report (AACTG, straightforward),  
T1 after 4–5 months, T2 8–18 months  
after T1
Aiii, n=1
ei, n=1
eii, n=2
No (U: no, M: NR)
No (U: no, M: NR)
Yes (U: yes, M: NR)
0 of 6
Nilsson Schönnesson47 Sweden; patients recruited  
by clinic nurses
203, 29% 45 (9), 22% Mean year of  
diagnosis =1990
Self-report (straightforward),  
24 months
Ai, n=3
Aii, n=1
Aiii, n=2
Bii, n=2
Ci, n=1
Ciii, n=2
D, n=1
ei, n=3
eii, n=1
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
1 of 6
Thrasher48 USA; patients in public use  
of HCSUS data set
1,911, 33%§§ Minority versus non-minority:  
,35: 35% minority group, 30%  
non-minority group. % female:  
33% versus 12%, respectively
Mean year first  
diagnosed with  
Hiv: 1992, minority  
group; 1990,  
non-minority group
Self-report (straightforward), 12 months Ciii, n=1
ei, n=2
No (U: no, M: NR)
Yes (U: yes, M: NR)
1 of 6
Horne49 UK; outpatients, eligible  
to receive HAART
136, 14% 38 (9), NR 5 years Self-report (straightforward), 12 months Ai, n=2
ei, n=1
Yes (U: yes, M: yes)
No (U: no, M: NT)
3 of 6
Mugavero50 USA; patients receiving care  
at infectious disease clinics
474, 39% 40 (median),  
35–46 (iQR), 29%
NR Self-report (AACTG, straightforward),  
27 months
eii, n=4 No (U: yes, M: no) 3 of 6
Carrieri51 France; patients starting  
HAART-regimen
1,110, 13% 37 (median), 22% First time since first  
positive Hiv-test in  
years: 3.8 (median),  
0.5–8.2 (iQR)
Self-report (AACTG, straightforward),  
60 months
Cii, n=1
ei, n=1
Yes (U: yes, M: yes)
Yes (U: yes, M: yes)
2 of 6
Transplant-related (immunosuppressant medication)
Stilley52 USA; transplant patients,  
recruited before hospital  
discharge or at early clinic visit
152, 29% 55 (10), 33% NR MeMS, 6 months Bi, n=1
Cii, n=1
D, n=2
ei, n=1
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
1 of 6
De Geest53 Belgium; convenience sample  
of outpatients
101, 0% 56 (median),  
20–69 (range), 13%
3 (median), 1–6 
(range) years since  
transplantation
MeMS, 6 months Aiii, n=1
Ciii, n=1
ei, n=1
eii, n=1
Yes (U: NR, M: yes)
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
2 of 6
Russell54 USA; convenience sample  
of renal transplant patients
50, 26% 60 (5), 38% NR MeMS, 12 months Aiii, n=1
Ciii, n=1
ei, n=2
No (U: no, M: NR)
No (U: no, M: NR)
No (U: no, M: NR)
0 of 6
weng55 USA; patients recruited at time  
of renal transplantation
829, 66% 48 (median),  
39–57 (iQR), 39%
NR MeMS, 12 months post-transplantation Aiii, n=1
Cii, n=1
ei, n=1
eii, n=1
No (U: yes, M: no)
No (U: no, M: NT)
No (U: no, M: NT)
No (U: no, M: NT)
2 of 6
Dew56 USA; heart transplant patients  
from academic hospital|| ||
108, 22% ,50 years: 49%, (female): 16% NR Self-report (straightforward),  
12 months post-transplantation
Aiii, n=1
Bi, n=2
Bii, n=1
Cii, n=2
ei, n=3
No (U: no, M: NT)
No (U: no, M: NT)
Yes (U: yes, M: yes)
No (U: no, M: no)
No (U: no, M: no)
2 of 6
Dew57 USA; patients receiving first  
lung transplantation in academic  
hospital
178, 29% 37% ,50 years, (female): 48% NR Self-report (straightforward), 24 months Aiii, n=3
Cii, n=2
D, n=1
ei, n=3
No (U: yes***, M: no)
No (U: yes, M: no)
No (U: yes, M: no)
No (U: yes, M: no)
1 of 6
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Table 2 (Continued)
First author Setting Sample characteristics Measures and results
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Study selection
Studies were selected based on the criteria in Table 1.
Studies exclusively recruiting subpopulations in special 
conditions (like prisoners, pregnant women) were excluded. 
Their results only pertain to a specific group of patients, 
therefore, including them might have introduced bias into 
this systematic review.
Two reviewers (BvdB and HZ) independently assessed 
studies for eligibility in two phases: 1) screening based 
on title and abstract; and 2) screening based on full text. 
Disagreements between BvdB and HZ were resolved by 
discussion; a third reviewer (CvdE) made decisions in case 
disagreements could not be resolved. Studies in Spanish or 
Portuguese were judged by LvdA. During the study selec-
tion process, three authors were contacted about statistics, 
outcome measure, or study design to determine eligibility 
for this review.20–22
Data extraction and quality assessment
For data extraction, a literature-based, standard form was 
developed.23,24 Information regarding study setting, design, 
descriptive statistics, measures, and analysis were extracted 
by HZ; BvdB arbitrarily selected 15% of the included studies 
to check appropriateness of all extracted data of these studies, 
and also checked all doubts indicated on the form by HZ.
If multiple adherence measures were presented in one 
study (eg, about dosing, timing, or taking medication)25, we 
only extracted data about taking medication. Two authors were 
contacted during the extraction process to check the duration of a 
follow-up period of $3 months26 or to explain ambiguities.19
We adapted the framework developed by Hayden et al27 to 
judge methodologic study quality. Our framework contained 
23 items divided into six bias domains: study participation, 
study attrition, prognostic, outcome and confounding mea-
surement, and analyses. Each item was scored as ‘yes’ (no 
unacceptable amount of bias introduced), ‘partly’ (/unsure), 
and ‘no’ (unacceptable amount of bias introduced). For 
every bias domain, a transparent method was used to reach 
overall judgment about the presence or absence of bias (see 
Table S1). Studies with $four domains judged as ‘yes’ were 
considered high-quality studies; studies with ,four domains 
were considered low-quality studies.
Using three randomly selected studies not included in the 
review, the framework was piloted by BvdB and HZ, who 
also performed the actual quality assessment.  Disagreements 
were resolved by discussion and, when necessary, a third 
reviewer (CvdE) made final decisions. On the domain level, 
a weighted extent of agreement between BvdB and HZ 
 (quadratic weighting scheme) was calculated due to the 
ordinal nature of the scores.28,29
Data synthesis and analysis
Because over 70 non-identical psychosocial predictors (non-
identical by name and/or measurement instrument) were 
studied in this review, and because of the variety of instru-
ments used to measure non-adherence, a qualitative instead 
Table 2 (Continued)
First author Setting Sample characteristics Measures and results
Sample size,  
% loss to follow-up
Age†, % female Disease duration† Adherence‡, follow-up period§ Psychosocial category,  
number of predictors||
Association present between category  
and adherence/non-adherence?¶
Number domains 
bias free**
Dobbels58 Belgium; heart, liver and lung  
transplant patients listed at  
university hospitals
186, 24% 52 (12), 33% NR Self-report (straightforward), 12 months  
post-transplantation
Ciii, n=2
D, n=5
ei, n=2
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
1 of 6
Other (diabetes and/or hypertension and/or heart disease)
DiMatteo59 USA; patients from five medical  
specialties in HMOs, large  
multispecialty groups or solo  
practices‡‡,¶¶
Max 1,828, UD 60 (8), 54% NR Self-report (straightforward), 24 months Bii, n=1
Ci, n=2
Ciii, n=1
eii, n=1
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
Yes (U: NR, M: yes)
0 of 6
Notes: *NS (non significant): as reported in the concerning study. UD (undetermined): because of inadequate description in the concerning study; †mean (and for age: 
standard deviation) in years reported unless indicated otherwise; ‡with straightforward, we mean that participants were directly asked to indicate how many medication doses 
they missed. For example: “How many pills did you take this week?”; §follow-up period = number of months between baseline (unless indicated otherwise) and last adherence 
measurement; ||this column shows the number of psychosocial predictors measured in the concerning study, and the assigned psychosocial category. Details about the single 
predictors are presented in Table S2. A = Beliefs and cognitions about I) medication and treatment; II) illness; III) self-efficacy and locus of control. B = coping styles i) task 
oriented, ii) emotion oriented. C = Social influences and social support I) regarding medical caregiver; II) regarding friends and family; III) in general. D = personality traits. 
e = psychological well-being: i) mood state; ii) perceived stress/stressors; ¶no = no significant association between psychosocial category and medication adherence/non-
adherence within study when P#0.05; Yes = significant association when P#0.05; U: univariate; M: multivariate; **to determine methodological quality, six bias domains per 
study were judged. Here, the total amount of bias free domains is reported (for further details, see Table S3); ††retrospective design; ‡‡diagnosis for coronary heart disease, 
hypertension, diabetes mellitus, and/or hyperlipidemia; §§% loss to follow-up assumed by HZ/BvdB; || ||type of medication is immunosuppressants, antihypertensives, and/or 
antivirals; ¶¶use of chronic preventive medication assumed; ***significance of P#0.05 assumed by HZ/BvdB.
Abbreviations: AACTG, adult AiDS clinical trials group; HAART, highly active antiretroviral therapy; HBS, health behavior scale; HCSUS, Hiv cost and services utilization 
study; HIV, human immunodeficiency virus; HMO, health maintenance organization; IQR, interquartile range; MARS, medication adherence report scale; MEMS, medication 
event monitoring system; NR, not reported; NS, non significant; NT, not tested; UD, undetermined.
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of a quantitative analysis was considered to be appropriate.30 
Therefore, the results regarding associations between psy-
chosocial predictors and medication non-adherence were 
qualitatively synthesized in four steps.
In step 1, psychosocial categories were formulated. 
Initially, all psychosocial elements as mentioned in general 
health behavior models and theories31,32 were listed (HZ). 
Subsequently, based on consensus, the elements were 
clustered by HZ and three psychologists (SvD, JV, and LK) 
resulting in the categories of Figure 1.
Next, the psychosocial predictors within the studies of the 
review were assigned to one of the categories in Figure 1 (HZ 
and the psychologists). In this way, the considerable number 
of single, non-identical predictors was dealt with.
In step 2, for each psychosocial predictor within a 
category and within a study, the presence of a significant 
univariate and multivariate association with medication 
non-adherence was determined (see Table S2). Statistical 
significance was set at P,0.05.
In step 3, results within studies were synthesized per 
psychosocial category. When $75% of variables within a 
single psychosocial category were significantly and con-
sistently (ie, same predictors in same direction) associated 
with non-adherence, a ‘yes’ was assigned (ie, association 
present). When $75% of variables were significantly, but 
inconsistently, associated (eg, four of five predictors in 
category about depressive symptoms, of which two are 
positively related to non-adherence and two are negatively 
related), the term ‘conflicting’ was assigned. When ,75% 
of variables were significantly and consistently associated, a 
‘no’ was assigned. Multivariate results were preferably used 
to synthesize results in this step. When multivariate results 
were not reported, univariate results were used.
In the fourth and final step, a best evidence synthe-
sis (BES) per psychosocial category between studies 
was performed to summarize evidence of longitudinal 
 associations between the predictors in the psychosocial 
Table 2 (Continued)
First author Setting Sample characteristics Measures and results
Sample size,  
% loss to follow-up
Age†, % female Disease duration† Adherence‡, follow-up period§ Psychosocial category,  
number of predictors||
Association present between category  
and adherence/non-adherence?¶
Number domains 
bias free**
Dobbels58 Belgium; heart, liver and lung  
transplant patients listed at  
university hospitals
186, 24% 52 (12), 33% NR Self-report (straightforward), 12 months  
post-transplantation
Ciii, n=2
D, n=5
ei, n=2
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
1 of 6
Other (diabetes and/or hypertension and/or heart disease)
DiMatteo59 USA; patients from five medical  
specialties in HMOs, large  
multispecialty groups or solo  
practices‡‡,¶¶
Max 1,828, UD 60 (8), 54% NR Self-report (straightforward), 24 months Bii, n=1
Ci, n=2
Ciii, n=1
eii, n=1
No (U: NR, M: no)
No (U: NR, M: no)
No (U: NR, M: no)
Yes (U: NR, M: yes)
0 of 6
Notes: *NS (non significant): as reported in the concerning study. UD (undetermined): because of inadequate description in the concerning study; †mean (and for age: 
standard deviation) in years reported unless indicated otherwise; ‡with straightforward, we mean that participants were directly asked to indicate how many medication doses 
they missed. For example: “How many pills did you take this week?”; §follow-up period = number of months between baseline (unless indicated otherwise) and last adherence 
measurement; ||this column shows the number of psychosocial predictors measured in the concerning study, and the assigned psychosocial category. Details about the single 
predictors are presented in Table S2. A = Beliefs and cognitions about I) medication and treatment; II) illness; III) self-efficacy and locus of control. B = coping styles i) task 
oriented, ii) emotion oriented. C = Social influences and social support I) regarding medical caregiver; II) regarding friends and family; III) in general. D = personality traits. 
e = psychological well-being: i) mood state; ii) perceived stress/stressors; ¶no = no significant association between psychosocial category and medication adherence/non-
adherence within study when P#0.05; Yes = significant association when P#0.05; U: univariate; M: multivariate; **to determine methodological quality, six bias domains per 
study were judged. Here, the total amount of bias free domains is reported (for further details, see Table S3); ††retrospective design; ‡‡diagnosis for coronary heart disease, 
hypertension, diabetes mellitus, and/or hyperlipidemia; §§% loss to follow-up assumed by HZ/BvdB; || ||type of medication is immunosuppressants, antihypertensives, and/or 
antivirals; ¶¶use of chronic preventive medication assumed; ***significance of P#0.05 assumed by HZ/BvdB.
Abbreviations: AACTG, adult AiDS clinical trials group; HAART, highly active antiretroviral therapy; HBS, health behavior scale; HCSUS, Hiv cost and services utilization 
study; HIV, human immunodeficiency virus; HMO, health maintenance organization; IQR, interquartile range; MARS, medication adherence report scale; MEMS, medication 
event monitoring system; NR, not reported; NS, non significant; NT, not tested; UD, undetermined.
A .          Beliefs and cognitions
I     About medication and treatment
II    About illness
III   Regarding self-efficacy and locus of control
B .          Coping styles
I     Task-oriented
II    Emotion-oriented
C .          Social influences and social support 
I     Regarding medical caregiver
II    Regarding friends and family 
III   In general
D .          Personality traits
E .          Psychosocial well-being
I     Mood state
II    Perceived stress(ors)
Figure 1 Psychosocial categories.
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categories and medication non-adherence. We defined four 
levels of evidence as used in previous reviews of longitu-
dinal studies:60 –62
1.	 Strong evidence: consistent findings ($75% of studies 
within psychosocial category report same conclusion 
about association; ie, ‘yes, present’ or ‘no, not present’) 
in at least two high-quality studies.
2.	 Moderate evidence: consistent findings in one high-
quality study AND at least two low-quality studies.
3.	 Limited evidence: findings in one high-quality study OR 
consistent findings in at least two low-quality studies.
4.	 Conflicting evidence: inconsistent findings in at least 
two studies irrespective of study quality (ie, ,75% 
of studies report same conclusion about association). 
Note that this level of evidence was checked first before 
assigning strong, moderate or limited evidence level to 
a category.
The level of evidence was undeterminable when #one 
study of low quality was available for a psychosocial 
category.
Sensitivity analyses were performed to examine the 
robustness of findings, regarding the cut-off point for 
methodological quality, diseases, adherence measurement, 
and statistical analyses (ie, focusing on univariate analyses 
only). Also, an additional analysis on single predictors was 
carried out, since associations between single predictors 
like ‘avoidance coping’ and non-adherence could be over-
shadowed by combining them into a single category with 
generally  non-significant psychosocial predictors, such as 
hopelessness and confusion. Three steps were taken: 1) all 
significant predictors (P#0.05) were listed; 2) each of these 
predictors was grouped with identically named, significant 
and non-significant predictors; and 3) when at least two 
studies were available for those predictors, the BES rules 
were applied.
Results
Study inclusion
Of 4,732 non-duplicate references, 30 met our inclusion cri-
teria (Figure 2).19,25,26,33–59 In all, 1,255 records were identified 
by screening the reference lists and the ISI Web of Knowledge 
citation index of the initial included studies.
Initially, the percentage of agreement regarding the eligi-
bility of studies was 86% (of the 272 studies selected on title 
and abstract, agreement was obtained in about 235 studies 
after reading the full-text). Disagreements were mainly due 
to misconceptions about psychosocial predictors (eg, clini-
cally diagnosed depression versus symptoms of depression), 
study design, and adherence measure (ie, discontinuation or 
execution adherence). For one study,52 disagreement could 
not be resolved by discussion and thus a final decision was 
made by CvdE.
Study characteristics and quality 
assessment
Table 2 displays study characteristics, measures, and results. 
A comprehensive table of measures and results is presented 
in Table S2.
The included studies (all based on different data sets) 
covered CPMMs for asthma, diabetes, heart diseases/hyper-
tension, human immunodeficiency virus (HIV), and organ 
transplants. Medication type was not explicitly mentioned in 
four studies,37,38,45,59 but we assumed CPMM was used since 
CPMM is the standard medical treatment for the 20 selected 
diseases in this review. In most studies, patients were recruited 
from medical clinics or hospitals and the sample size 
ranged from 50–1,911. Attrition rates varied from 0%–71%. 
 Participants were predominantly men and often $37 years of 
age and a disease duration of .2 years. The observation period 
between baseline and last adherence measurement was $3 
and ,12 months in ten studies and $12 months in 20 studies, 
with a maximum of 60 months. Medication adherence was 
mostly measured by self-report (18 studies, predominantly 
questionnaires); seven studies used a validated adherence 
questionnaire.33,36,43,46,49–51 Other adherence measurements 
were carried out by reviewing medical records or the medica-
tion event monitoring system (MEMS). In 15 studies, both 
univariate and multivariate analyses were reported.
All 30 included studies were judged to be ‘low-quality’ 
(Table S3). This was mainly due to poor descriptions and/
or bias regarding the study sample, the use of non-validated 
questionnaires, the lack of accounting for confounding 
variables, and a poor description of the data analyses. Most 
studies, moreover, did not appropriately describe actions 
taken in case of missing data.
A total of 180 bias domains were judged (30 studies 
by six domains). Initially, BvdB and HZ fully agreed on 
78 domains, partially agreed (ie, ‘partly’ versus ‘no’ or 
‘partly’ versus ‘yes’) on 79 domains and fully disagreed 
(eg, ‘yes’ versus ‘no’) on 23 domains, resulting in a 
weighted agreement of 76%. Disagreements were caused 
by poor description of methods, different interpretations 
of missing data, differences in calculating study attrition 
rates, and different interpretations regarding the appro-
priateness of study sample descriptions. On this latter 
point,  disagreements about three studies35,48,52 could not be 
resolved by discussion between BvdB and HZ and, thus, 
CvdE made the final decision.
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database search
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Records identified by citation index
and hand search
n=1,255   
Double records removed
n=188 
Records screened on title and
abstract
n=4,732 
Records
excluded
n=4,460  
Did not meet inclusion criteria: n=4,459
Study not available: n=1 
Full-text articles assessed
for eligibility
n=272
Full-text articles
excluded
n=242 
No longitudinal study design or too short
follow-up period (<3 months): n=141 
No psychosocial predictors: n=31
Type of adherence measure (eg,
discontinuation, persistence): n=26  
Adherence not primary outcome
measure: n=15 
<18 years: n=12
No CPMM: n=6
Living in non-Western country: n=4
No somatic, chronic disease as
specified in search strategy: n=2 
Other (eg, thesis): n=5
Full-text articles meeting selection
criteria / included
n=30   
Figure 2 Flowchart of study inclusion process.
Abbreviation: CPMM, chronic preventive maintenance medication.
Best evidence synthesis
Table 3 shows there is limited evidence for the absence of a 
longitudinal association with medication non-adherence in 
all of the eleven psychosocial subcategories.
Beliefs and cognitions
Regarding category AI (beliefs and cognitions about 
medication and treatment), two of nine studies found a 
longitudinal, multivariate association between having a 
positive attitude towards taking medication and adher-
ence (odds ratio [OR] =1.56, 95% confidence interval [CI] 
1.18, 2.06),43 and between necessity beliefs and concern 
beliefs about medication and adherence (OR =2.19, 95% 
CI 1.02, 4.71 and OR =0.45, 95% CI 0.22, 0.96, respec-
tively).49 One other study33 found univariate associations 
between necessity and concern beliefs about medication 
and adherence, but these associations did not hold in the 
multivariate analysis.
One study demonstrated a longitudinal, multivariate 
association between low self-efficacy and medication 
non-adherence;53 however, the effect size was small. 
Univariate, but not multivariate associations between 
self-efficacy and adherence were demonstrated in two 
studies.55,57
Coping styles
No univariate and multivariate associations were found 
between the task-oriented coping style category and medica-
tion adherence.
Regarding emotion-oriented coping styles, one of six studies 
revealed a multivariate association with non- adherence (eg, OR 
of 9.71 for avoidance coping).56  Furthermore, avoidance cop-
ing as a single predictor was associated with non-adherence in 
three of four studies measuring this construct.25,40,56
Social influences and social support
Two of the 25 studies demonstrated significant associations 
between predictors within the category social influences and 
social support and (non-)adherence, but only one of these 
studies reported on a multivariate association between having 
support from a partner and non-adherence (regression coef-
ficient =−0.15, 95% CI −0.25, −0.05).51 Receiving practical 
social support was associated with better adherence as a single 
predictor.38,41
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Personality traits
One of eight studies showed a multivariate, longitudinal 
association between the category of personality traits and 
medication non-adherence:26 a lower sense of coherence 
(a global life orientation in which life is perceived as com-
prehensible, manageable and meaningful)63 was associated 
with greater non-adherence (OR=0.55, CI 0.31–0.96). Asso-
ciations between other predictors within the personality traits 
category and non-adherence were lacking.
Psychological well-being
Regarding categories EI (mood state) and EII (perceived 
stress/stressors), no associations between predictors in 
those categories and medication non-adherence could be 
established for the vast majority of studies (24 out of 29). 
Two of the five studies which did show significant asso-
ciations reported on multivariate analyses: the regression 
coefficient for depressive symptoms was 0.18 (95% CI 0.07, 
0.29) in predicting non-adherence;51 the standardized beta 
for health distress was −0.22 (CI not reported) for predict-
ing adherence.59
Table S2 can be consulted for detailed information about 
associations between single psychosocial predictors and 
medication adherence/non-adherence.
Sensitivity analyses
The sensitivity analyses confirmed that, generally, no 
association was found between the psychosocial catego-
ries and medication non-adherence (Table S4).
The additional analysis on single predictors showed no 
association between most single, psychosocial predictors and 
medication non-adherence. However, conflicting evidence 
was found for having a positive attitude towards taking 
medication,37,43 necessity beliefs and concern beliefs about 
medication,33,49 self-efficacy in medication-taking,25,33,43,47,53,54 
the coping style “planful problem solving”,25,41 and (the 
number of) stressful (life) events.38,42,46 Limited evidence was 
found for an association between escape-avoidance coping 
and medication non-adherence,25,41,56,59 and for an association 
between receiving practical, social support and medication 
adherence.38,41
Discussion
To the best of our knowledge, this is the first systematic 
review summarizing evidence of longitudinal associations 
between psychosocial factors and non-adherence to CPMM, 
irrespective of somatic disease. Due to the low quality of the 
included studies, limited evidence was found for absence of 
longitudinal associations between categories of psychoso-
Table 3 Level of evidence for longitudinal associations between psychosocial categories and medication non-adherence
Psychosocial category N of studies Quality Longitudinal association Level of evidence
A. Beliefs and cognitions
        i.  About medication  
and treatment
9 All low 2 × yes43,49 
7	×	no19,25,33,36,37,45,47
No association 
(limited evidence)
      ii. About illness 3 All low 3	×	no19,36,47 No association 
(limited evidence)
    III.  Self-efficacy and locus of control 10 All low 1	×	yes53 
9	×	no25,33,43,46,47,54–56,57
No association 
(limited evidence)
B. Coping styles
      i. Task-oriented 4 All low 4	×	no25,41,52,56 No association 
(limited evidence)
    ii. emotion-oriented 6 All low 1	×	yes56 
5	×	no25,40,41,47,59
No association 
(limited evidence)
C.  Social influences and social support
        i. Regarding medical caregiver 5 All low 1	×	yes45 
4	×	no19,43,47,59
No association 
(limited evidence)
      ii. Regarding friends and family 6 All low 1	×	yes51 
5	×	no37,52,55–57
No association 
(limited evidence)
    iii. in general 14 All low 14	×	no19,25,35,36,38,40,41,43,47,48,53,54,58,59 No association 
(limited evidence)
D. Personality traits 8 All low 1	×	yes26 
7	×	no25,42,43,47,52,57,58
No association 
(limited evidence)
e. Psychosocial well-being
      i. Mood state 21 All low 3	×	yes44,48,51 
18	×	no19,25,26,34,39–42,46,47,49,52–58
No association 
(limited evidence)
    ii. Perceived stress/stressors 8 All low 2	×	yes46,59 
6	×	no19,42,47,50,53,55
No association 
(limited evidence)
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cial predictors and medication non-adherence. In general, 
findings were robust according to sensitivity analyses.
Our f indings of longitudinal associations between 
psychosocial factors and medication non-adherence are in 
line with the few conducted cross-sectional studies about 
associations between medication adherence, coping styles, 
personality traits, and psychosocial well-being (except 
depressive symptoms) in somatic conditions. The findings 
in these cross-sectional studies are ambiguous at best.8,64–68 
For example, an active coping style was associated with 
medication adherence in some studies8,68 but not in others,64,66 
and stress was associated with lesser adherence in a study of 
Holt et al,67 but was unrelated to non-adherence in a study 
of Ediger et al.65
In contrast to coping styles and personality traits, depres-
sion is often studied as possible predictor of medication 
non-adherence. Here, our results are not in line with results 
from other reviews, reporting depression to be a predictor 
of medication non-adherence.6,69–74 Initially, this discrepancy 
might be explained by the fact that clinical depression is 
within the scope of most other studies, but beyond the scope 
of our systematic review since we did not study morbidity as 
a predictor of non-adherence; instead, we studied depressive 
symptoms. Second, an explanation might be that those other 
reviews included studies with mainly cross-sectional designs. 
Feelings of depression might increase and decrease over the 
course of a disease. A high degree of depressive feelings 
might correlate well with non-adherent behavior at that same 
time, but just might not be predictive of non-adherent behav-
ior in the future due to this changeability. Thus, longitudinal 
associations between depressive feelings and non-adherence 
might not be applicable.
This thought might also apply to discrepancies in find-
ings between our review and other reviews on associations 
between beliefs about medication/treatment, poor social sup-
port, and non-adherence. These other reviews underline the 
importance of beliefs about medication/treatment and poor 
social support in predicting medication non-adherence6,10,69–76 
in contrast to our review findings, but again, those other 
reviews are mainly based on studies with cross-sectional 
designs.
In terms of internal validity, a strength of this review 
is that we, in contrast to others, systematically defined and 
categorized psychosocial factors. By doing so, we were 
able to 1) draw a concise number of conclusions about 
associations between psychosocial predictors and medica-
tion non-adherence in a reproducible manner; 2) address 
the heterogeneity between single, psychosocial predictors; 
and 3) address an important goal of a systematic review: 
converging information. The pitfall of categorization (eg, the 
possibility of overlooking significant associations between 
certain, single predictors and non-adherence, by pooling 
them with other types of [non-significant] predictors), was 
avoided by performing an extended sensitivity analysis on 
single predictors. This analysis revealed our conclusions 
to be robust for almost all single, psychosocial predictors 
included in this review.
Another strength of this review is that we systematically 
synthesized results using a best evidence synthesis in con-
trast to most other reviews, which tend to be characterized 
by narrative designs.6,10,69,70,73,74,76 Narrative designs often do 
not rely on systematic methods to assign weight of evidence; 
eg, by incorporating methodological quality of included stud-
ies.77 Although no review procedure eliminates the chance 
that reviewers’ biases will affect the conclusions drawn,77 
the application of a best evidence synthesis makes a review 
procedure transparent and reproducible.
A limitation of this systematic review is that we used 
chronic disease terms instead of medication terms in the 
search strategy and, consequently, we may have missed 
relevant studies about chronic preventive maintenance 
medication. However, we assume that the number of missed 
studies is minimal, since diseases are usually mentioned in 
medication adherence studies.
Another limitation could be the use of results of univari-
ate analyses to draw conclusions about associations in the 
absence of multivariate analysis data, as univariate analyses 
could lead to an overestimating of the strength of  associations. 
However, our sensitivity analyses on data from univariate 
analyses confirmed the robustness of our findings.
Concerning external validity, a strong feature of this 
review is that it focused exclusively on longitudinal asso-
ciations between psychosocial predictors and medication 
non-adherence, thereby providing insight into the temporal-
ity and robustness of associations. However, only 5 of the 
30 studies included in our review corrected for baseline 
non-adherence.34,50,53,58,59 Failure to account for baseline 
non-adherence when suggesting predictive longitudinal 
associations is considered a liberal approach,78 since baseline 
non-adherence is likely to explain a substantial part of the 
variance in non-adherence over time. Because we did not find 
any associations using a liberal approach, however, we believe 
it is unlikely that handling a strict longitudinal approach in 
this review would have altered our findings.
Another limitation concerning external validity is that 
the poor quality of the included studies prevented us from 
 drawing firm conclusions about the lack of associations 
between psychosocial predictors and medication adherence 
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The lack of a gold standard for adherence measurement73 also 
restricts the validity of our findings. The adherence measures 
used in the included studies of this review (self-report, refill 
data, and electronic monitoring) do not measure actual inges-
tion, and the use of self-report and electronic monitoring 
might have introduced response bias because of participants’ 
awareness of the  measurements. However, all medication 
adherence related research has to deal with the limitations of 
adherence  measurements. For now, our review provides the 
best evidence currently available, and clearly demonstrates 
the need for more high-quality, longitudinal research into 
associations between psychosocial predictors and medica-
tion non-adherence.
Two recommendations for future research can be made. 
First, future longitudinal research into psychosocial predic-
tors of medication non-adherence should be of high quality. 
Researchers should, for example, use valid measures of 
psychosocial predictors and medication non-adherence and 
should thoroughly describe which steps were performed in 
the study, especially those relating to handling missing data 
and avoiding bias.
Second, the research gap in longitudinal studies into 
associations between psychosocial predictors and medication 
non- adherence in patients with conditions such as rheumatic 
diseases, migraine disorders, gout, glaucoma, and stomach 
ulcers (see Supplementary Materials) should be complemented. 
Although we assume that review findings will also apply to 
these diseases, this assumption needs to be confirmed.
The conclusion of this systematic review is that there is 
limited evidence for absence of longitudinal associations 
between psychosocial predictors and medication non-
 adherence. Consequently, our results do not provide psy-
chosocial targets for the development of new interventions 
in clinical practice. However, the usefulness of psychosocial 
predictors in improving medication adherence should not be 
ruled out, as more high-quality research is needed to confirm 
or refute the conclusion of this review. Such future research 
could also further explore the associations found in this 
review between escape-avoidance coping and medication 
non-adherence, and between receiving practical, social sup-
port and medication adherence.
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Supplementary materials
Pubmed search strategy
(((adult[MeSH Terms] OR mature[tw] OR adult[tw])
AND
((Ischaemic heart diseases[TW] OR angina pectoris[TW] 
OR Myocardial Ischemia[TW] OR asthma[TW] OR 
Diabetes mellitus[TW] OR diabetes mellitus[TW] 
OR hypercholesterolaemia[TW] OR hyperlipidaemia[TW] 
OR Dyslipidemias[TW] OR Gastric ulcer[TW] OR Duode-
nal ulcer[TW] OR Stomach Ulcer[TW] OR glaucoma[TW] 
OR glaucoma[TW] OR heart failure[TW] OR Heart 
failure[TW] OR arrhythmias[TW] OR Arrhythmias, 
Cardiac[TW] OR “Human immunodef iciency virus” 
OR HIV disease[TW] OR HIV-disease[TW] OR HIV 
infections[TW] OR HIV-infections[TW] OR Hyperten-
sive diseases[TW] OR Hypertension[TW] OR Ulcerative 
colitis[TW] OR Crohn’s disease[TW] OR Inflamma-
tory Bowel Diseases[TW] OR Arthropathies[TW] OR 
gout[TW] OR Malignant neoplasm of breast[TW] OR Breast 
Neoplasms[TW] OR Hereditary angioedema[TW] OR 
Angioedemas, Hereditary[TW] OR transplantation[TW] OR 
Organ Transplanta t ion[TW] OR mig raine[TW] 
OR Migraine Disorders[TW] OR osteoporosis[TW] 
OR arthropathy[TW] OR Systemic connective tissue 
disorders[TW] OR psoriatic arthropathy[TW] OR rheuma-
toid arthritis[TW] OR Systemic lupus erythematosus[TW] 
OR Systemic sclerosis[TW] OR Arthritis, Psoriatic[TW] 
OR Arthritis, Rheumatoid[TW] OR Lupus Erythemato-
sus, Systemic[TW] OR Scleroderma, Systemic[TW] OR 
Arterial embolism[TW] OR thrombosis[TW] OR venous 
embolism[TW] OR Embolism and Thrombosis[TW] OR 
Paget Disease[TW] OR Osteitis Deformans[TW]) OR 
(Myocardial Ischemia[MH] OR asthma[MH] OR diabe-
tes mellitus[MH] OR Dyslipidemias[MH] OR Stomach 
Ulcer[MH] OR glaucoma[MH] OR Heart failure[MH] OR 
Arrhythmias, Cardiac[MH] OR HIV infections[MH] OR 
Hypertension[MH] OR Inflammatory Bowel Diseases[MH] 
OR gout[MH] OR Breast Neoplasms[MH] OR Angioe-
demas, Hereditary[MH] OR Organ Transplantation[MH] 
OR Migraine Disorders[MH] OR osteoporosis[MH] OR 
Arthritis, Psoriatic[MH] OR Arthritis, Rheumatoid[MH] 
OR Lupus Erythematosus, Systemic[MH] OR Scleroderma, 
Systemic[MH] OR Embolism and Thrombosis[MH] OR 
Osteitis Deformans[MH]))
AND
((medication adherence[MH] OR patient compliance[MH]) 
OR (medication compliance[TW] OR medication non-
compliance[TW] OR medication non compliance[TW] 
OR medication noncompliance[TW] OR medication 
adherence[TW] OR medication non-adherence[TW] 
OR medication non adherence[TW] OR medication 
nonadherence[TW] OR medication adherance[TW] OR 
medication non-adherance[TW] OR medication non 
adherance[TW] OR medication nonadherance[TW] OR med-
ication persistence[TW] OR medication non-persistence[TW] 
OR medication non persistence[TW] OR medication 
nonpersistence[TW] OR medication persistance[TW] 
OR medication non-persistance[TW] OR medication non 
persistance[TW] OR medication nonpersistance[TW] 
OR medicine compliance[TW] OR medicine non-
compliance[TW] OR medicine non compliance[TW] OR 
medicine noncompliance[TW] OR medicine adherence[TW] 
OR medicine non-adherence[TW] OR medicine non 
adherence[TW] OR medicine nonadherence[TW] OR medicine 
adherance[TW] OR medicine non-adherance[TW] OR medi-
cine non adherance[TW] OR medicine nonadherance[TW] 
OR medicine persistence[TW] OR medicine non-
persistence[TW] OR medicine non persistence[TW] OR 
medicine nonpersistence[TW] OR medicine persistance[TW] 
OR medicine non-persistance[TW] OR medicine non 
persistance[TW] OR medicine nonpersistance[TW] OR 
medical compliance[TW] OR medical non-compliance[TW] 
OR medical  non compliance[TW] OR medical 
noncompliance[TW] OR medical adherence[TW] OR medi-
cal non-adherence[TW] OR medical non adherence[TW] OR 
medical nonadherence[TW] OR medical adherance[TW] 
OR medical non-adherance[TW] OR medical non 
adherance[TW] OR medical nonadherance[TW] OR medical 
persistence[TW] OR medical non-persistence[TW] OR medi-
cal non persistence[TW] OR medical nonpersistence[TW] 
OR medical  persistance[TW] OR medical  non-
persistance[TW] OR medical non persistance[TW] OR 
medical nonpersistance[TW] OR drug compliance[TW] OR 
drug non-compliance[TW] OR drug non compliance[TW] 
OR drug noncompliance[TW] OR drug adherence[TW] OR 
drug non-adherence[TW] OR drug non adherence[TW] OR 
drug nonadherence[TW] OR drug adherance[TW] OR drug 
non-adherance[TW] OR drug non adherance[TW] OR drug 
nonadherance[TW] OR drug persistence[TW] OR drug non-
persistence[TW] OR drug non persistence[TW] OR drug 
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nonpersistence[TW] OR drug persistance[TW] OR drug non-
persistance[TW] OR drug non persistance[TW] OR drug 
nonpersistance[TW] OR drugs compliance[TW] OR drugs 
non-compliance[TW] OR drugs non compliance[TW] OR 
drugs noncompliance[TW] OR drugs adherence[TW] OR 
drugs non-adherence[TW] OR drugs non adherence[TW] 
OR drugs nonadherence[TW] OR drugs adherance[TW] OR 
drugs non-adherance[TW] OR drugs non adherance[TW] 
OR drugs nonadherance[TW] OR drugs persistence[TW] OR 
drugs non-persistence[TW] OR drugs non persistence[TW] 
OR drugs nonpersistence[TW] OR drugs persistance[TW] OR 
drugs non-persistance[TW] OR drugs non persistance[TW] 
OR drugs nonpersistance[TW]))
AND
(Prospective Studies[MH] OR Longitudinal Studies[MH] OR 
Cohort Studies[MH] OR Follow-up Studies[MH] OR Ret-
rospective Studies[MH] OR Prospective Studies[TIAB] OR 
Longitudinal Studies[TIAB] OR Cohort Studies[TIAB] OR 
Follow-up Studies[TIAB] OR Retrospective Studies[TIAB] 
OR observational stud*[TIAB] OR predict*[TW] OR 
prognos*[TW] OR prognostic factor*[TW] OR course[TW] 
OR determinant*[TW]))
NOT
“Africa”[Mesh] OR “Latin America”[Mesh] OR 
“Asia,  Central”[Mesh] OR “Borneo”[Mesh] OR 
“Brunei”[Mesh] OR “Cambodia”[Mesh] OR “East 
Timor”[Mesh] OR “Laos”[Mesh] OR “Malaysia”[Mesh] 
OR “Mekong Valley”[Mesh] OR “Myanmar”[Mesh] 
OR “Philippines”[Mesh] OR “Singapore”[Mesh] OR 
“ T h a i l a n d ” [ M e s h ]  O R  “ Vi e t n a m ” [ M e s h ]  O R 
“Bangladesh”[Mesh] OR “Bhutan”[Mesh] OR “India”[Mesh] 
OR “Afghanistan”[Mesh] OR “Bahrain”[Mesh] OR 
“Iran”[Mesh] OR “Egypt”[Mesh] OR “Iraq”[Mesh] OR 
“Israel”[Mesh] OR “Jordan”[Mesh] OR “Kuwait”[Mesh] 
OR “Lebanon”[Mesh] OR “Oman”[Mesh] OR “Qatar”[Mesh] 
OR “Saudi Arabia”[Mesh] OR “Syria”[Mesh] OR 
“United Arab Emirates”[Mesh] OR “Yemen”[Mesh] 
OR “Nepal”[Mesh] OR “Pakistan”[Mesh] OR “Sri 
Lanka”[Mesh] OR “China”[Mesh] OR “Korea”[Mesh] OR 
“Mongolia”[Mesh] OR “Taiwan”[Mesh]
NOT
(youth[TIAB] OR child*[TIAB] )
NOT
(Clinical Trial[MH] OR case reports[PT] OR review[PT] 
OR meta-analysis[MH] OR Cross-sectional Studies[MH] 
OR Case-control Studies[MesH:NoExp] OR Clinical 
Trial*[PT] OR case report*[PT] OR review*[PT] OR meta-
analys*[PT] OR case report*[TIAB] OR case-report*[TIAB] 
OR review*[TIAB] OR systematic review*[TIAB] 
OR meta-analys*[TIAB] OR randomized controlled 
trial*[TIAB] OR randomised controlled trial*[TIAB] OR 
clinical trial*[TIAB] OR controlled clinical trial*[TIAB] 
OR cross-sectional*[TIAB] OR cross sectional*[TIAB] OR 
Case-control Studies[TIAB] OR case-control[TIAB] OR 
case control[TIAB] OR Editorial[ptyp] OR Letter[ptyp] 
OR Comment[ptyp] OR Interview[ptyp] OR Newspaper 
Article[ptyp])
Chronic preventive maintenance 
medication
A02BA01 Cimetidine
A02BA02 Ranitidine
A02BA03 Famotidine
A02BA04 Nizatidine
A02BA07 Ranitidinebismutcitrate
A02BB01 Misoprostol
A02BC01 Omeprazole
A02BC02 Pantoprazole
A02BC03 Lansoprazole
A02BC04 Rabeprazole
A02BC05 Esomeprazole
A07EA04 Betamethasone
A07EA06 Budesonide
A07EA07 Beclomethasone
A07EC01 Sulphasalazine
A07EC02 Mesalazine
A07EC03 Olsalazine
A10A Insulin
A10BA02 Metformin
A10BB01 Glibenclamide
A10BB03 Tolbutamide
A10BB07 Glipizide
A10BB09 Gliclazide
A10BB12 Glimepiride
A10BF01 Acarbose
A10BG02 Rosiglitazone
A10BG03 Pioglitazone
A10BH01 Sitagliptine
A10BX02 Repaglinide
A11CC03 Alfacalcidol
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A11CC04 Calcitriol
A11CC05 Colecalciferol
A12AA01 Calciumphosphate
A12AA02 Calciumglubionate
A12AA03 Calciumgluconate
A12AA04 Calciumcarbonate
A12AA05 Calciumlactate
A12AA07 Calciumchloride
A12AA12 Calciumacetate
A12AA30 Calciumlevulinate
B01AA03 Warfarin
B01AA04 Fenprocoumon
B01AA07 Acenocoumarol
B01AC04 Clopidogrel
B01AC06 Acetylsalicylic acid
B01AC07 Dipyridamole
B01AC08 Carbasalate calcium
B01AC09 Epoprostenol
B01AC21 Treprostinil
B03BB01 Folic acid
C01AA05 Digoxin
C01BA01 Quinine
C01BA02 Procainamide
C01BA03 Disopyramide
C01BB01 Lidocaine
C01BB04 Aprindine
C01BC03 Propafenone
C01BC04 Flecainide
C01BD01 Amiodarone
C01DA08 Isosorbidedinitrate
C01DA14 Isosorbidemononitrate
C01DX16 Nicorandil
C01EB17 Ivabradine
C02AB01 Methyldopa
C02CA01 Prazosin
C02CA04 Doxazosin
C02CA06 Urapidil
C02DB02 Hydralazine
C02DC01 Minoxidil
C02KD01 Ketanserin
C02KX01 Bosentan
C02KX03 Sitaxentan
C03AA03 Hydrochloorthiazide
C03AA04 Chlorthiazide
C03BA04 Chlortalidone
C03BA11 Indapamide
C03CA01 Furosemide
C03CA02 Bumetanide
C03DA01 Spironolactone
C03DA04 Eplerenone
C03DB01 Amiloride
C03DB02 Triamterene
C04AC01 Nicotinic acid
C04AD02 Xantinolnicotinate
C07AA02 Oxprenolol
C07AA03 Pindolol
C07AA05 Propranolol
C07AA07 Sotalol
C07AB02 Metoprolol
C07AB03 Atenolol
C07AB04 Acebutolol
C07AB05 Betaxolol
C07AB07 Bisoprolol
C07AB08 Celiprolol
C07AB12 Nebivolol
C07AG01 Labetalol
C07AG02 Carvedilol
C08CA01 Amlodipine
C08CA02 Felodipine
C08CA03 Isradipine
C08CA04 Nicardipine
C08CA05 Nifedipine
C08CA06 Nimodipine
C08CA07 Nisoldipine
C08CA08 Nitrendipine
C08CA09 Lacidipine
C08CA12 Barnidipine
C08CA13 Lercanidipine
C08DA01 Verapamil
C08DB01 Diltiazem
C09AA01 Captopril
C09AA03 Lisinopril
C09AA04 Perindopril
C09AA05 Ramipril
C09AA06 Quinapril
C09AA07 Benazepril
C09AA08 Cilazapril
C09AA09 Fosinopril
C09AA10 Trandolapril
C09AA15 Zofenopril
C09CA01 Losartan
C09CA02 Eprosartan
C09CA03 Valsartan
C09CA04 Irbesartan
C09CA06 Candesartan
C09CA07 Telmisartan
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C09CA08 Olmesartan
C10AA01 Simvastatin
C10AA03 Pravastatin
C10AA04 Fluvastatin
C10AA05 Atorvastatin
C10AA07 Rosuvastatin
C10AB01 Clofibrate
C10AB02 Bezafibrate
C10AB04 Gemfibrozil
C10AB08 Ciprofibrate
C10AC01 Colestyramine
C10AC02 Colestipol
C10AC04 Colesevelam
C10AD02 Nicotinic acid
C10AD06 Acipimox
C10AX09 Ezetimib
G03XA01 Danazol
G03XC01 Raloxifene
G04BD02 Flavoxate
G04BD04 Oxybutynin
G04BD07 Tolterodine
G04BD08 Solifenacin
G04BD10 Darifenacin
G04CA01 Alfuzosin
G04CA02 Tamsulosin
G04CA03 Terazosin
G04CB01 Finasterid
G04CB02 Dutasterid
H02AA02 Fludrocortisone
H02AB01 Betamethasone
H02AB02 Dexamethasone
H02AB04 Methylprednisolone
H02AB06 Prednisolone
H02AB07 Prednisone
H02AB08 Triamcinolone
H02AB09 Hydrocortisone
H02AB10 Cortisone
J05AE01 Saquinavir
J05AE02 Indinavir
J05AE03 Ritonavir
J05AE04 Nelfinavir
J05AE05 Amprenavir
J05AE06 Lopinavir
J05AE07 Fosamprenavir
J05AE08 Atazanavir
J05AE09 Tipranavir
J05AE10 Darunavir
J05AF01 Zidovudine
J05AF02 Didanosine
J05AF03 Zalcitabine
J05AF04 Stavudine
J05AF05 Lamivudin
J05AF06 Abacavir
J05AF07 Tenofovir
J05AF08 Adefovir
J05AF09 Emtricitabine
J05AF10 Entecavir
J05AF11 Telbivudine
J05AG01 Nevirapine
J05AG03 Efavirenz
J05AX07 Enfuvirtide
L01AA01 Cyclophosphamide
L01BA01 Methotrexate
L02BG01 Aminoglutethimide
L02BG03 Anastrozole
L02BG04 Letrozole
L04AA06 Mycophenol acid
L04AA10 Sirolimus
L04AA13 Leflunomide
L04AA18 Everolimus
L04AB01 Etanercept
L04AB02 Infliximab
L04AB04 Adalimumab
L04AC03 Anakinra
L04AD01 Ciclosporine
L04AD02 Tacrolimus
L04AX01 Azathioprine
L04AX03 Methotrexate
M01CB01 Aurothiomalate
M01CB03 Auranofin
M01CC01 Penicillamine
M04AA01 Allopurinol
M04AB01 Probenecid
M04AB03 Benzbromarone
M05BA01 Etidronate
M05BA02 Clodronate
M05BA03 Pamidronate
M05BA04 Alendronate
M05BA05 Tiludronate
M05BA06 Ibandronate
M05BA07 Risedronate
M05BA08 Zoledronate
M05BX03 Strontiumranelate
N02CX01 Pizotifen
N02CX02 Clonidine
R03BA01 Beclomethasone
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S01EC01 Acetazolamide
S01EC03 Dorzolamide
S01EC04 Brinzolamide
S01ED01 Timolol
S01ED02 Betaxolol
S01ED03 Levobunolol
S01ED04 Metipranolol
S01ED05 Carteolol
S01ED06 Befunolol
S01EE01 Latanoprost
S01EE03 Bimatoprost
S01EE04 Travoprost
R03BA02 Budesonide
R03BA05 Fluticasone
R03BA08 Ciclesonid
R03BC01 Cromolyn sodium
R03BC03 Nedocromil
R03DC03 Montelukast
S01EA02 Dipivefrine
S01EA03 Apraclonidine
S01EA05 Brimonidine
S01EA51 Epinephrine
S01EB01 Pilocarpine
S01EB08 Aceclidine
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Table S1 Framework for judging methodological quality
Bias domain Criterion Score Judgment Final score
1. Study participation 1.1.  The setting of the source population is adequately described by key characteristics (setting/geographical 
location)
 Yes  Partly  No 5 × yes = yes
1 × no = no
else = partly
 Yes
 Partly
 No
1.2.  The (baseline) study sample is adequately described by key characteristics (descriptive data about age, sex, 
diagnosis, disease duration and medication type/group), and no unacceptable level of bias is present
 Yes  Partly  No
1.3.  The method of recruitment or sampling is adequately described. if method of recruitment is not 
‘consecutive’, then, for example, descriptions are given about the sampling frame, numbers, methods to 
identify the sample (such as a description of referral patterns in health care) and period of recruitment, 
and no unacceptable level of bias is present
 Yes  Partly  No
1.4.  inclusion and exclusion criteria are adequately described, and no unacceptable level of bias is present  Yes  Partly  No
1.5.  There is adequate participation in the study by eligible individuals (power analysis is described or the sample 
size (n) is adequate in relation to the number of prognostic variables (K) in the statistical analyses (ratio n:K 
exceeds 10:1)
 Yes  Partly  No
2. Study attrition 2.1.  Response rate (ie, proportion of study sample completing the study and providing outcome data) is 
adequate 
if study sample size #50 participants: ‘yes’ when total number of participants lost to follow-up was ,10% at follow-
up $three months. ‘Partly’: if this percentage was between 10% and 20%. ‘No’: if this percentage was $20% if study 
sample size .50 participants: ‘yes’, when total number of participants lost to follow-up was ,20% at follow-up 
$three months. ‘Partly’: if this percentage was between 20% and 33%. ‘No’: if this percentage was $33%
 Yes  Partly  No 2.1 yes = yes (you can leave 2.2 open)
2.1 no = no
OR 2.1 partly, 2.2 no = no
else = partly
 Yes
 Partly
 No
2.2.  Attempts to collect information about participants who dropped out of the study are described:  
1) reasons for loss to follow-up are provided OR 2) participants lost to follow-up are adequately 
described by key characteristics and outcomes. No unacceptable level of bias is present
 Yes  Partly  No
3.  Prognostic factor  
measurement
3.1.  A clear description of the main prognostic factors is provided (not covariates) AND/OR measures/
methods regarding the main prognostic factors, at baseline and follow-up are adequately described to 
allow assessment of their validity and reliability. No unacceptable level of bias is present
     ○  Objective measures (such as number of life-changing events) and clear description is ‘yes’. Poor/no 
description = ‘partly’
     ○ validated, subjective measures (eg, opinions) and clear description = ‘yes’. Poor/no description = ‘partly’ 
        ○ Non-validated, subjective measures and clear description = ‘partly’. Poor/no description = ‘no’
 Yes  Partly  No 4 × yes = yes
3.1 or 3.2 no = no
OR 3.1 or 3.2 partly (no no’s), 3.3 or 3.4 no = no
else = partly
 Yes
 Partly
 No
3.2.  The method and setting of measurement are the same for all study participants at baseline and follow-up  Yes  Partly  No
3.3.  Continuous variables are reported or appropriate cut-off points are used  Yes  Partly  No
3.4.  Authors appropriately described and dealt with missing data on prognostic factors  Yes  Partly  No
4. Outcome measurement 4.1.  A clear description of medication adherence is provided AND/OR measures/methods of medication 
adherence (at baseline and follow-up) are adequately described, to allow assessment of their validity and 
reliability. No unacceptable level of bias is present 
○  Objective measures (such as pill count, refill rates, MEMS) and clear description = ‘yes’. Poor/no 
description is ‘partly’
      ○  validated, subjective measures (eg, questionnaires) and clear description = ‘yes’. Poor/no description = ‘partly’
      ○ Non-validated, subjective measures and clear description = ‘partly’. Poor/no description = ‘no’
 Yes  Partly  No 3 × yes = yes
4.1 or 4.2 no = no
OR 4.1 or 4.2 partly (no no’s), 4.3 no = no
else = partly
 Yes
 Partly
 No
4.2.  The method and setting of measurement are the same for all study participants at baseline (if measured) 
and follow-up
 Yes  Partly  No
4.3.  Authors appropriately described and dealt with missing outcome data  Yes  Partly  No
5.  Confounding measurement  
and account
5.1.  The most important confounders are measured 
Examples of possible confounders: age; socioeconomic status/educational level/financial situation/illiteracy; 
social support/networks; depression/anxiety/emotional distress/lack of acceptance of disease; fatigue/pain/
physical disability; self-efficacy/coping; regimen complexity/route of administration/number of medications; 
satisfaction with patient-provider relationship/autonomy
 Yes  Partly  No
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Table S1 Framework for judging methodological quality
Bias domain Criterion Score Judgment Final score
1. Study participation 1.1.  The setting of the source population is adequately described by key characteristics (setting/geographical 
location)
 Yes  Partly  No 5 × yes = yes
1 × no = no
else = partly
 Yes
 Partly
 No
1.2.  The (baseline) study sample is adequately described by key characteristics (descriptive data about age, sex, 
diagnosis, disease duration and medication type/group), and no unacceptable level of bias is present
 Yes  Partly  No
1.3.  The method of recruitment or sampling is adequately described. if method of recruitment is not 
‘consecutive’, then, for example, descriptions are given about the sampling frame, numbers, methods to 
identify the sample (such as a description of referral patterns in health care) and period of recruitment, 
and no unacceptable level of bias is present
 Yes  Partly  No
1.4.  inclusion and exclusion criteria are adequately described, and no unacceptable level of bias is present  Yes  Partly  No
1.5.  There is adequate participation in the study by eligible individuals (power analysis is described or the sample 
size (n) is adequate in relation to the number of prognostic variables (K) in the statistical analyses (ratio n:K 
exceeds 10:1)
 Yes  Partly  No
2. Study attrition 2.1.  Response rate (ie, proportion of study sample completing the study and providing outcome data) is 
adequate 
if study sample size #50 participants: ‘yes’ when total number of participants lost to follow-up was ,10% at follow-
up $three months. ‘Partly’: if this percentage was between 10% and 20%. ‘No’: if this percentage was $20% if study 
sample size .50 participants: ‘yes’, when total number of participants lost to follow-up was ,20% at follow-up 
$three months. ‘Partly’: if this percentage was between 20% and 33%. ‘No’: if this percentage was $33%
 Yes  Partly  No 2.1 yes = yes (you can leave 2.2 open)
2.1 no = no
OR 2.1 partly, 2.2 no = no
else = partly
 Yes
 Partly
 No
2.2.  Attempts to collect information about participants who dropped out of the study are described:  
1) reasons for loss to follow-up are provided OR 2) participants lost to follow-up are adequately 
described by key characteristics and outcomes. No unacceptable level of bias is present
 Yes  Partly  No
3.  Prognostic factor  
measurement
3.1.  A clear description of the main prognostic factors is provided (not covariates) AND/OR measures/
methods regarding the main prognostic factors, at baseline and follow-up are adequately described to 
allow assessment of their validity and reliability. No unacceptable level of bias is present
     ○  Objective measures (such as number of life-changing events) and clear description is ‘yes’. Poor/no 
description = ‘partly’
     ○ validated, subjective measures (eg, opinions) and clear description = ‘yes’. Poor/no description = ‘partly’ 
        ○ Non-validated, subjective measures and clear description = ‘partly’. Poor/no description = ‘no’
 Yes  Partly  No 4 × yes = yes
3.1 or 3.2 no = no
OR 3.1 or 3.2 partly (no no’s), 3.3 or 3.4 no = no
else = partly
 Yes
 Partly
 No
3.2.  The method and setting of measurement are the same for all study participants at baseline and follow-up  Yes  Partly  No
3.3.  Continuous variables are reported or appropriate cut-off points are used  Yes  Partly  No
3.4.  Authors appropriately described and dealt with missing data on prognostic factors  Yes  Partly  No
4. Outcome measurement 4.1.  A clear description of medication adherence is provided AND/OR measures/methods of medication 
adherence (at baseline and follow-up) are adequately described, to allow assessment of their validity and 
reliability. No unacceptable level of bias is present 
○  Objective measures (such as pill count, refill rates, MEMS) and clear description = ‘yes’. Poor/no 
description is ‘partly’
      ○  validated, subjective measures (eg, questionnaires) and clear description = ‘yes’. Poor/no description = ‘partly’
      ○ Non-validated, subjective measures and clear description = ‘partly’. Poor/no description = ‘no’
 Yes  Partly  No 3 × yes = yes
4.1 or 4.2 no = no
OR 4.1 or 4.2 partly (no no’s), 4.3 no = no
else = partly
 Yes
 Partly
 No
4.2.  The method and setting of measurement are the same for all study participants at baseline (if measured) 
and follow-up
 Yes  Partly  No
4.3.  Authors appropriately described and dealt with missing outcome data  Yes  Partly  No
5.  Confounding measurement  
and account
5.1.  The most important confounders are measured 
Examples of possible confounders: age; socioeconomic status/educational level/financial situation/illiteracy; 
social support/networks; depression/anxiety/emotional distress/lack of acceptance of disease; fatigue/pain/
physical disability; self-efficacy/coping; regimen complexity/route of administration/number of medications; 
satisfaction with patient-provider relationship/autonomy
 Yes  Partly  No
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Table S1 (Continued)
Bias domain Criterion Score Judgment Final score
5.2.  A clear description of the most important confounders measured is provided AND/OR measures/
methods of the most important confounders (at baseline) are adequately described to allow assessment of 
their validity and reliability. No unacceptable level of bias is present 
○ Objective measures (such as age, sex) and clear description = ‘yes’. Poor/no description is ‘partly’ 
○  validated, subjective measures (eg, opinions) and clear description = ‘yes’. Poor/no description = ‘partly’
       ○ Non-validated, subjective measures and clear description = ‘partly’. Poor/no description = ‘no’
 Yes  Partly  No One of 5.1 to 5.4 = no (if 5.1 no, you can leave 5.2 to 5.5 open)
OR 5.1 to 5.4 partly, 5.5 no = no
All partly = partly
OR 5.1 to 5.4 partly, 5.5 yes = partly
OR none of 5.1 to 5.4 no, 5.5 no = partly
OR 5.1 to 5.4 yes, 5.5 not yes = partly
else = yes
 Yes
 Partly
 No
5.3.  The method and setting of confounding measurement are the same for all study participants at baseline  Yes  Partly  No
5.4.  important potential confounders are accounted for in the study design (eg, matching for key variables/
restriction) OR in analysis (stratification/multivariate techniques)
 Yes  Partly  No
5.5.  Authors appropriately described and dealt with missing confounding data  Yes  Partly  No
6. Analysis 6.1.  There is sufficient presentation of data to assess the adequacy of the analysis 
‘Yes’, if main findings of the study and statistical methods used are clearly described: simple outcome data, 
crude data and estimates of random variability should be reported, so that the reader can check the major 
analyses and conclusions
 Yes  Partly  No 4 × yes = yes
At least 1 × no = no
else = partly
 Yes
 Partly
 No
6.2.  The statistical tests used to assess the main outcome are appropriate 
For example, non-parametric methods should be used for small sample sizes
 Yes  Partly  No
6.3.  The strategy for model building (ie, inclusion of variables) is appropriate, and is based on conceptual 
thoughts, a framework or a model 
For example: variables that do not correlate with the main outcome of interest are not used in 
multivariate analysis. Proper variables are entered in logical steps into the multivariate model
 Yes  Partly  No
6.4.  The selected model is adequate for the design of the study 
For example: in repeated measures, a repeated-measure model should be used. if outcome is binominal, 
logistic regression should be used, etcetera. if delta outcome is being investigated, models should to be 
adjusted for baseline outcome values
 Yes  Partly  No
Abbreviation: MeMS, medication event monitoring system.
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Table S1 (Continued)
Bias domain Criterion Score Judgment Final score
5.2.  A clear description of the most important confounders measured is provided AND/OR measures/
methods of the most important confounders (at baseline) are adequately described to allow assessment of 
their validity and reliability. No unacceptable level of bias is present 
○ Objective measures (such as age, sex) and clear description = ‘yes’. Poor/no description is ‘partly’ 
○  validated, subjective measures (eg, opinions) and clear description = ‘yes’. Poor/no description = ‘partly’
       ○ Non-validated, subjective measures and clear description = ‘partly’. Poor/no description = ‘no’
 Yes  Partly  No One of 5.1 to 5.4 = no (if 5.1 no, you can leave 5.2 to 5.5 open)
OR 5.1 to 5.4 partly, 5.5 no = no
All partly = partly
OR 5.1 to 5.4 partly, 5.5 yes = partly
OR none of 5.1 to 5.4 no, 5.5 no = partly
OR 5.1 to 5.4 yes, 5.5 not yes = partly
else = yes
 Yes
 Partly
 No
5.3.  The method and setting of confounding measurement are the same for all study participants at baseline  Yes  Partly  No
5.4.  important potential confounders are accounted for in the study design (eg, matching for key variables/
restriction) OR in analysis (stratification/multivariate techniques)
 Yes  Partly  No
5.5.  Authors appropriately described and dealt with missing confounding data  Yes  Partly  No
6. Analysis 6.1.  There is sufficient presentation of data to assess the adequacy of the analysis 
‘Yes’, if main findings of the study and statistical methods used are clearly described: simple outcome data, 
crude data and estimates of random variability should be reported, so that the reader can check the major 
analyses and conclusions
 Yes  Partly  No 4 × yes = yes
At least 1 × no = no
else = partly
 Yes
 Partly
 No
6.2.  The statistical tests used to assess the main outcome are appropriate 
For example, non-parametric methods should be used for small sample sizes
 Yes  Partly  No
6.3.  The strategy for model building (ie, inclusion of variables) is appropriate, and is based on conceptual 
thoughts, a framework or a model 
For example: variables that do not correlate with the main outcome of interest are not used in 
multivariate analysis. Proper variables are entered in logical steps into the multivariate model
 Yes  Partly  No
6.4.  The selected model is adequate for the design of the study 
For example: in repeated measures, a repeated-measure model should be used. if outcome is binominal, 
logistic regression should be used, etcetera. if delta outcome is being investigated, models should to be 
adjusted for baseline outcome values
 Yes  Partly  No
Abbreviation: MeMS, medication event monitoring system.
Patient Preference and Adherence 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
544
Zwikker et al
Table S2 explanation of measures and results*
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Asthma (inhaled corticosteroids)
Ponieman1 USA; patients from general internal  
medicine clinic, n=261
Adherence by self-report  
(MARS), 3 months
(items derived from BMQ and Self-Regulation Theory):  
concerns beliefs: worried about side effects of iCS?
Concerns beliefs: worried about getting addicted to iCS?
Concerns beliefs: if i use iCS all the time they will stop working
Necessity beliefs: important to use iCS when symptomatic?
Necessity beliefs: important to use iCS when asymptomatic?
Self-efficacy: confident in ability to use ICS as prescribed
Self-efficacy: confident in ability to control asthma
Self-efficacy: confident in controlling future health
Ai
Ai
Ai
Ai
Ai
Aiii
Aiii
Aiii
OR =0.3 (0.2, 0.7), P,0.05
OR =0.4 (0.2, 0.8), P,0.05
OR =0.4 (0.2, 0.9), P,0.05
NS
OR =5.8 (2.3, 14.6), P,0.05
OR =3.5 (1.6, 7.6), P,0.05
NS
NS
OR =0.52 (0.36, 0.74), P,0.001
NS‡‡
NS‡‡
NS‡‡
OR =4.15 (2.54, 6.77), P,0.001
OR =2.23 (1.42, 3.52), P,0.001
NS‡‡
NS‡‡
U: − 
M: −
U: − 
M: 0
U: − 
M: 0
U: 0 
M: 0
U: + 
M: +
U: + 
M: +
U: 0 
M: 0
U: 0 
M: 0
0 of 6
Diabetes (oral and/or parenteral anti-diabetics)
venturini2,§§ USA; patients from HMO-providing  
health services, n=786
Adherence by record  
review (continuous  
measure corrected for  
self-reported baseline  
adherence), last time  
point flexible, but within  
24 months
Perception of mental health (mood state, SF-36) ei NR NS U: NR 
M: 0
2 of 6
Heart disease and hypertension (cardiovascular medication)
Gazmararian3,|| || USA; community-dwelling patients,  
n=1,549
Non-adherence  
by record review,  
12 months
Social support (instrument NR) Ciii NS NT U: 0 
M: NT
3 of 6
Nabi4 Finland: local government  
employees, n=1,021
Non-adherence by  
record review (ordinal  
measure), 12 months
Anxiety (ATS)
Hostility (FTSSH)
Optimism (LOT-R)
Pessimism (LOT-R)
Psychological distress (GHQ)
Sense of coherence (SOC)
ei
D
D
D
ei
D
NS
NS
NS
NS
NS
OR =0.62 (0.36, 1.05), P,0.10
NT
NT
NT
NT
NT
OR =0.55 (0.31, 0.96), P,0.05
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: +
1 of 6
Grégoire5 Canada: hypertensive adults with  
prescription from network  
of pharmacies, n=692
Non-adherence by self- 
report (Morisky Scale),  
3 months
(Interview, self-developed items): beliefs concerning efficacy  
of antihypertensive medication
Beliefs concerning hypertension as risk factor for  
other diseases
How much are you at risk of a heart attack because of your 
hypertension if you follow your doctor’s advice?
How much are you at risk of a stroke because of your 
hypertension if you follow your doctor’s advice?
Ai
Aii
Aii
Aii
NS
“No effect” versus “a lot of effect”  
(ref cat): OR =1.74 (1.08, 2.81), P=0.02
NS
NS
NS
“No effect” versus “a lot of effect”:  
OR =2.00 (1.21, 3.33), P#0.05
NS
NS
U: 0 
M: 0
U: − 
M: −
U: 0 
M: 0
U: 0 
M: 0
0 of 6
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Table S2 explanation of measures and results*
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Asthma (inhaled corticosteroids)
Ponieman1 USA; patients from general internal  
medicine clinic, n=261
Adherence by self-report  
(MARS), 3 months
(items derived from BMQ and Self-Regulation Theory):  
concerns beliefs: worried about side effects of iCS?
Concerns beliefs: worried about getting addicted to iCS?
Concerns beliefs: if i use iCS all the time they will stop working
Necessity beliefs: important to use iCS when symptomatic?
Necessity beliefs: important to use iCS when asymptomatic?
Self-efficacy: confident in ability to use ICS as prescribed
Self-efficacy: confident in ability to control asthma
Self-efficacy: confident in controlling future health
Ai
Ai
Ai
Ai
Ai
Aiii
Aiii
Aiii
OR =0.3 (0.2, 0.7), P,0.05
OR =0.4 (0.2, 0.8), P,0.05
OR =0.4 (0.2, 0.9), P,0.05
NS
OR =5.8 (2.3, 14.6), P,0.05
OR =3.5 (1.6, 7.6), P,0.05
NS
NS
OR =0.52 (0.36, 0.74), P,0.001
NS‡‡
NS‡‡
NS‡‡
OR =4.15 (2.54, 6.77), P,0.001
OR =2.23 (1.42, 3.52), P,0.001
NS‡‡
NS‡‡
U: − 
M: −
U: − 
M: 0
U: − 
M: 0
U: 0 
M: 0
U: + 
M: +
U: + 
M: +
U: 0 
M: 0
U: 0 
M: 0
0 of 6
Diabetes (oral and/or parenteral anti-diabetics)
venturini2,§§ USA; patients from HMO-providing  
health services, n=786
Adherence by record  
review (continuous  
measure corrected for  
self-reported baseline  
adherence), last time  
point flexible, but within  
24 months
Perception of mental health (mood state, SF-36) ei NR NS U: NR 
M: 0
2 of 6
Heart disease and hypertension (cardiovascular medication)
Gazmararian3,|| || USA; community-dwelling patients,  
n=1,549
Non-adherence  
by record review,  
12 months
Social support (instrument NR) Ciii NS NT U: 0 
M: NT
3 of 6
Nabi4 Finland: local government  
employees, n=1,021
Non-adherence by  
record review (ordinal  
measure), 12 months
Anxiety (ATS)
Hostility (FTSSH)
Optimism (LOT-R)
Pessimism (LOT-R)
Psychological distress (GHQ)
Sense of coherence (SOC)
ei
D
D
D
ei
D
NS
NS
NS
NS
NS
OR =0.62 (0.36, 1.05), P,0.10
NT
NT
NT
NT
NT
OR =0.55 (0.31, 0.96), P,0.05
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: +
1 of 6
Grégoire5 Canada: hypertensive adults with  
prescription from network  
of pharmacies, n=692
Non-adherence by self- 
report (Morisky Scale),  
3 months
(Interview, self-developed items): beliefs concerning efficacy  
of antihypertensive medication
Beliefs concerning hypertension as risk factor for  
other diseases
How much are you at risk of a heart attack because of your 
hypertension if you follow your doctor’s advice?
How much are you at risk of a stroke because of your 
hypertension if you follow your doctor’s advice?
Ai
Aii
Aii
Aii
NS
“No effect” versus “a lot of effect”  
(ref cat): OR =1.74 (1.08, 2.81), P=0.02
NS
NS
NS
“No effect” versus “a lot of effect”:  
OR =2.00 (1.21, 3.33), P#0.05
NS
NS
U: 0 
M: 0
U: − 
M: −
U: 0 
M: 0
U: 0 
M: 0
0 of 6
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First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
How much are you at risk of heart attack because of your 
hypertension if you do not do anything about it?
How much are you at risk of stroke because of your 
hypertension if you do not do anything about it?
Social support (Pearlin et al31)
Aii
Aii
Ciii
“Do not know” versus “no to moderate risk” (ref cat): 
OR =0.46 (0.19, 1.12), P=0.09
“Do not know” versus “no to moderate risk” (ref cat): 
OR =0.44 (0.17, 1.16), P=0.10
NS
NS
“Do not know” versus “no to 
moderate risk”: OR =0.40 (0.15, 
1.09), P=0.07
NS
U: 0 
M: 0
U: 0 
M: 0
U: 0 
M: 0
Miller6,§§§ Site not reported: patients from  
institutions providing cardiac  
rehabilitation programs, n=141
Adherence by self-report  
(continuous measure,  
HBS), 6–9 months
Attitude towards medication taking (MAS)
Beliefs about which steps of the medical regimen people most 
important to them think they should perform (HiS)
Ai
Cii
NR NS
NS
U: NR 
M: 0
U: NR 
M: 0
0 of 6
Molloy7,§§§ UK; patients admitted to one of  
four London hospitals with Acute  
Coronary Syndrome, n=295
Adherence by self-report,  
12 months
emotional support (derived from Berkman et al32 and  
Seeman et al33)
Practical support
Ciii
Ciii
NS
Number of patients providing practical support:  
0: 39.7% adherent. 1: 40.5% adherent. Two or  
more: 59.2% adherent, P=0.004
NS
OR =2.12 (1.06, 4.26),  
P=0.03
U: 0 
M: 0
U: + 
M: +
1 of 6
HIV (antiretroviral medication)
Deschamps8 Belgium; outpatients of university  
hospital, n=60
Non-adherence by  
MeMS, 5–6 months after  
measuring psychosocial  
constructs
Anxiety (AMHi)
Coping style: confrontational (AwC)
Coping style: distancing
Coping style: self-controlling
Coping style: seek social support
Coping style: accept responsibility
Coping style: escape-avoidance (higher score = more  
escape-avoidance)
Coping style: planful problem solving (higher score = more 
planful problem solving)|| || ||
Coping style: positive reappraisal
Depression (AMHi)
Perceived benefits of treatment (APIAQ)
Perceived severity of seriousness of implications when not 
taking medications adequately
Perceived susceptibility of developing AiDS when not taking 
medications as prescribed
Positive affect (eg, happiness person)
Received social support (AGSRP)
Self-efficacy in taking HAART medication (ALTMBSES)
ei
Bi
Bii
Bii
Ciii
Bii
Bii
Bi
Bi
ei
Ai
Ai
Ai
D
Ciii
Aiii
NS
NS
NS
NS
NS
NS
Adherent patients 7.2, (2.2) versus non- 
adherent patients 10.1 (2.8), P=0.003
Adherent patients 7.5 (median), 3 (iQR) versus non-
adherent patients 9 (median), 2 (iQR), P=0.049
NS
NS
Adherent patients 21 (3.5) versus non- 
adherent patients 18.7 (3.9), P=0.07
NS
NS
NS
NS
NS
NR U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: − 
M: NR
U: − 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
1 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
How much are you at risk of heart attack because of your 
hypertension if you do not do anything about it?
How much are you at risk of stroke because of your 
hypertension if you do not do anything about it?
Social support (Pearlin et al31)
Aii
Aii
Ciii
“Do not know” versus “no to moderate risk” (ref cat): 
OR =0.46 (0.19, 1.12), P=0.09
“Do not know” versus “no to moderate risk” (ref cat): 
OR =0.44 (0.17, 1.16), P=0.10
NS
NS
“Do not know” versus “no to 
moderate risk”: OR =0.40 (0.15, 
1.09), P=0.07
NS
U: 0 
M: 0
U: 0 
M: 0
U: 0 
M: 0
Miller6,§§§ Site not reported: patients from  
institutions providing cardiac  
rehabilitation programs, n=141
Adherence by self-report  
(continuous measure,  
HBS), 6–9 months
Attitude towards medication taking (MAS)
Beliefs about which steps of the medical regimen people most 
important to them think they should perform (HiS)
Ai
Cii
NR NS
NS
U: NR 
M: 0
U: NR 
M: 0
0 of 6
Molloy7,§§§ UK; patients admitted to one of  
four London hospitals with Acute  
Coronary Syndrome, n=295
Adherence by self-report,  
12 months
emotional support (derived from Berkman et al32 and  
Seeman et al33)
Practical support
Ciii
Ciii
NS
Number of patients providing practical support:  
0: 39.7% adherent. 1: 40.5% adherent. Two or  
more: 59.2% adherent, P=0.004
NS
OR =2.12 (1.06, 4.26),  
P=0.03
U: 0 
M: 0
U: + 
M: +
1 of 6
HIV (antiretroviral medication)
Deschamps8 Belgium; outpatients of university  
hospital, n=60
Non-adherence by  
MeMS, 5–6 months after  
measuring psychosocial  
constructs
Anxiety (AMHi)
Coping style: confrontational (AwC)
Coping style: distancing
Coping style: self-controlling
Coping style: seek social support
Coping style: accept responsibility
Coping style: escape-avoidance (higher score = more  
escape-avoidance)
Coping style: planful problem solving (higher score = more 
planful problem solving)|| || ||
Coping style: positive reappraisal
Depression (AMHi)
Perceived benefits of treatment (APIAQ)
Perceived severity of seriousness of implications when not 
taking medications adequately
Perceived susceptibility of developing AiDS when not taking 
medications as prescribed
Positive affect (eg, happiness person)
Received social support (AGSRP)
Self-efficacy in taking HAART medication (ALTMBSES)
ei
Bi
Bii
Bii
Ciii
Bii
Bii
Bi
Bi
ei
Ai
Ai
Ai
D
Ciii
Aiii
NS
NS
NS
NS
NS
NS
Adherent patients 7.2, (2.2) versus non- 
adherent patients 10.1 (2.8), P=0.003
Adherent patients 7.5 (median), 3 (iQR) versus non-
adherent patients 9 (median), 2 (iQR), P=0.049
NS
NS
Adherent patients 21 (3.5) versus non- 
adherent patients 18.7 (3.9), P=0.07
NS
NS
NS
NS
NS
NR U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: − 
M: NR
U: − 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
1 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Holmes9 USA; Hiv-clinic patients, n=116 Adherence by MeMS,  
12 months (or when viral  
load of $1,000 copies/mL  
was reached)
Depressive symptoms (CeS-D)
Hiv-disclosure worries (HAT-QOL)
Health worries (higher score = fewer worries)
Medication worries (higher score = fewer worries)
Provider trust
Social support (iSeL)
Stress (PSS)
ei
Aii
Aii
Ai
Ci
Ciii
eii
High adherence 12.6 (11.3),  
low adherence 16.5 (11.7), P=0.06
NS
High adherence 79.2 (23.9),  
low adherence 70.4 (28.9), P=0.06
High adherence 86.1 (20.4),  
low adherence 83.3 (18.3), P=0.06
NS
NS
High adherence 12.4 (7.8),  
low adherence 15.3 (8.2), P=0.07
NS
NT
NS
NS
NT
NT
NS
U: 0 
M: 0
U: 0 
M: NT
U: 0 
M: 0
U: 0 
M: 0
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: 0
2 of 6
Delgado10 Canada; patients enrolled in  
community drug treatment  
program, n=316
Adherence by record  
review, 12 months
Depressive symptoms (CeS-D) ei Not reporting depression: 79.8%  
adherent, reporting depression: 68.1%  
adherent, P=0.02
NS U: − 
M: 0
1 of 6
Singh11 USA; new veteran patients seen  
at medical center, n=52
Non-adherence by  
record review, 6 months
Confusion and bewilderment (POMS)
Depression and dejection
Mood disturbance
Religious support (instrument NR)
Social support (instrument NR)
Symptoms of depression (BDi)
Tension and anxiety (POMS)
Bii
ei
ei
Ciii
Ciii
ei
ei
NS
Adherent 14.2 (SeM 1.9), non-adherent  
22.1 (SeM 3.4), P=0.04
39% in adherent patients, 76% in  
non-adherent patients, P=0.03
NS
NS
NS
NS
NT
NS
OR =1.4 (1.1, 1.8), P=0.01
NT
NT
NT
NT
U: 0 
M: NT
U: − 
M: 0
U: − 
M: −
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
1 of 6
Singh12 Site not reported: patients in  
Hiv-medical centers, n=138
Non-adherence by  
record review, 6 months
Coping style: active-behavioral focused (higher score = greater 
applicability of coping style to patient, BMiCiS)
Coping style: active-cognitive focused
Coping style: avoidant coping
Coping style: emotion-focused
Coping style: problem-focused
Hopelessness: future expectations
Hopelessness: loss of motivation (higher score = more 
hopelessness, BHS)
Hopelessness: negative feelings about future
Hopelessness: total score
Quality of life: psychological functioning (MOS SF-36)
Satisfaction with social support: emotional (SSQ)
Bi
Bi
Bii
Bii
Bi
Bii
Bii
Bii
Bii
ei
Ciii
(Mean score, SeM): non-adherent 5.2  
(0.5) versus adherent 6.6 (0.2), P=0.01
NS
Non-adherent 3.3 (0.3) versus adherent  
2.6 (0.2), P=0.02
NS
Non-adherent 6.0 (0.5) versus adherent  
7.1 (0.2), P=0.02
NS
Non-adherent 1.75 (0.5), adherent  
0.6 (0.1), P=0.006
NS
NS
NS
NS
NR U: + 
M: NR
U: 0 
M: NR
U: − 
M: NR
U: 0 
M: NR
U: + 
M: NR
U: 0 
M: NR
U: − 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
1 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Holmes9 USA; Hiv-clinic patients, n=116 Adherence by MeMS,  
12 months (or when viral  
load of $1,000 copies/mL  
was reached)
Depressive symptoms (CeS-D)
Hiv-disclosure worries (HAT-QOL)
Health worries (higher score = fewer worries)
Medication worries (higher score = fewer worries)
Provider trust
Social support (iSeL)
Stress (PSS)
ei
Aii
Aii
Ai
Ci
Ciii
eii
High adherence 12.6 (11.3),  
low adherence 16.5 (11.7), P=0.06
NS
High adherence 79.2 (23.9),  
low adherence 70.4 (28.9), P=0.06
High adherence 86.1 (20.4),  
low adherence 83.3 (18.3), P=0.06
NS
NS
High adherence 12.4 (7.8),  
low adherence 15.3 (8.2), P=0.07
NS
NT
NS
NS
NT
NT
NS
U: 0 
M: 0
U: 0 
M: NT
U: 0 
M: 0
U: 0 
M: 0
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: 0
2 of 6
Delgado10 Canada; patients enrolled in  
community drug treatment  
program, n=316
Adherence by record  
review, 12 months
Depressive symptoms (CeS-D) ei Not reporting depression: 79.8%  
adherent, reporting depression: 68.1%  
adherent, P=0.02
NS U: − 
M: 0
1 of 6
Singh11 USA; new veteran patients seen  
at medical center, n=52
Non-adherence by  
record review, 6 months
Confusion and bewilderment (POMS)
Depression and dejection
Mood disturbance
Religious support (instrument NR)
Social support (instrument NR)
Symptoms of depression (BDi)
Tension and anxiety (POMS)
Bii
ei
ei
Ciii
Ciii
ei
ei
NS
Adherent 14.2 (SeM 1.9), non-adherent  
22.1 (SeM 3.4), P=0.04
39% in adherent patients, 76% in  
non-adherent patients, P=0.03
NS
NS
NS
NS
NT
NS
OR =1.4 (1.1, 1.8), P=0.01
NT
NT
NT
NT
U: 0 
M: NT
U: − 
M: 0
U: − 
M: −
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
1 of 6
Singh12 Site not reported: patients in  
Hiv-medical centers, n=138
Non-adherence by  
record review, 6 months
Coping style: active-behavioral focused (higher score = greater 
applicability of coping style to patient, BMiCiS)
Coping style: active-cognitive focused
Coping style: avoidant coping
Coping style: emotion-focused
Coping style: problem-focused
Hopelessness: future expectations
Hopelessness: loss of motivation (higher score = more 
hopelessness, BHS)
Hopelessness: negative feelings about future
Hopelessness: total score
Quality of life: psychological functioning (MOS SF-36)
Satisfaction with social support: emotional (SSQ)
Bi
Bi
Bii
Bii
Bi
Bii
Bii
Bii
Bii
ei
Ciii
(Mean score, SeM): non-adherent 5.2  
(0.5) versus adherent 6.6 (0.2), P=0.01
NS
Non-adherent 3.3 (0.3) versus adherent  
2.6 (0.2), P=0.02
NS
Non-adherent 6.0 (0.5) versus adherent  
7.1 (0.2), P=0.02
NS
Non-adherent 1.75 (0.5), adherent  
0.6 (0.1), P=0.006
NS
NS
NS
NS
NR U: + 
M: NR
U: 0 
M: NR
U: − 
M: NR
U: 0 
M: NR
U: + 
M: NR
U: 0 
M: NR
U: − 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
1 of 6
(Continued)
Patient Preference and Adherence 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
550
Zwikker et al
Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Satisfaction with social support: informational  
(higher scores = less satisfaction)
Satisfaction with social support: tangible
Satisfaction with social support: total score
Ciii
Ciii
Ciii
Non-adherent 7.9 (1.1), adherent 6.1 (0.3), P=0.04
Non-adherent 7.7 (1.1), adherent  
5.5 (0.3), P=0.07
Non-adherent 22.9 (3.3), adherent  
16.8 (0.75), P=0.03
U: + 
M: NR
U: 0 
M: NR
U: + 
M: NR
Bottonari13 USA; patients treated in  
immunodeficiency clinic, n=78
Adherence by self- 
report (straightforward),  
6–9 months
Depressive symptoms (iDD)
experience of general (stressful) life events (LeS)
HIV-specific (stressful) life events (BHLES)
Neuroticism: personality style indicative of affective instability 
(NSePQSS)
ei
eii
eii
D
NS
NS
NS
NS
NR U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
0 of 6
Perceived stress (PSS)
Self-esteem (RSeQR)
eii
D
OR =0.88 (0.77, 0.98), P=0.04
NS
U: − 
M: NR
U: 0 
M: NR
Godin14 Canada; patients from medical  
Hiv-clinics, n=400
Adherence over  
time by self-report  
(straightforward),  
12 months
Change in predictors related to adherence over time: attitude 
towards medication-taking (more positive attitude = greater 
adherence, self-developed scale)
Optimism (DOS)
Outcome expectations (eg, believe that specific course of 
action will lead to desired outcome, self-developed scale)
Patient-doctor satisfaction (Pat SS)
Self-efficacy regarding medication taking (self-developed scale)
Social support (SPS)
Ai
D
Aiii
Ci
Aiii
Ciii
NR OR =1.56 (1.18, 2.06), P#0.05
NS
NS
NS
OR =1.68 (1.27, 2.22), P#0.05
NS
U: NR 
M: +
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: +
U: NR 
M: 0
1 of 6
Kacanek15 USA; patients recruited by media  
and physician networks, n=225
Suboptimal adherence  
by self-report  
(straightforward):  
max 30 months
Development of depressive symptoms (BST) ei Suboptimal adherence in those who  
developed depressive symptoms =45.1%  
versus 25.9% in those with no  
depressive symptoms, P=0.01
NT U: − 
M: NT
2 of 6
Martini16,§§§ italy; outpatients using combination  
therapy, n=214
Adherence by self- 
report (ordinal measure,  
straightforward  
questionnaire),  
12 months
(interview, instrument NR): perception of therapy: reliable?
Perception of therapy: enslaving?
Satisfied about doctor/patient discussion regarding clinical and 
therapeutic aspects of treatment?
Ai
Ai
Ci
in “high adherence” category, therapy  
perceived as “reliable” by 15.6%, and “not reliable”  
by 84.4%. in “variable adherence” cat 4.8% versus 
95.2%. in “low adherence” cat 0% versus  
100%, P=0.02
NS
in “high adherence” category:  
“sufficient/highly satisfied” = 73.9%,  
“little/not satisfied” =26.1%. in “variable  
adherence” cat 80% versus 20%. in  
“low adherence” cat 50% versus 50%, P=0.05
NR U: + 
M: NR
U: 0 
M: NR
U: ? 
M: NR
0 of 6
Mellins17 USA; Hiv-infected mothers  
recruited in waiting room  
of adult clinic, n=128
Non-adherence by  
self-report (AACTG,  
straightforward),  
T1 after 4–5 months,  
T2 8–18 months after T1
Negative stressful events (Pei)
Parenting stress (low scores = more stress, PPCS)
Psychological distress (aggregated demoralization score, 
DSPeRi)
Self-efficacy in carrying out health-related behaviors  
(Chesney et al34)
eii
eii
ei
Aiii
OR =1.27 (1.09, 1.49), P,0.01 at T1,  
OR =1.28 (1.05, 1.57), P=0.02 at T2
OR =0.86 (0.76, 0.98), P=0.02 at T2
NS
NS
NR U: − 
M: NR
U: − 
M: NR
U: 0 
M: NR
U: 0 
M: NR
0 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Satisfaction with social support: informational  
(higher scores = less satisfaction)
Satisfaction with social support: tangible
Satisfaction with social support: total score
Ciii
Ciii
Ciii
Non-adherent 7.9 (1.1), adherent 6.1 (0.3), P=0.04
Non-adherent 7.7 (1.1), adherent  
5.5 (0.3), P=0.07
Non-adherent 22.9 (3.3), adherent  
16.8 (0.75), P=0.03
U: + 
M: NR
U: 0 
M: NR
U: + 
M: NR
Bottonari13 USA; patients treated in  
immunodeficiency clinic, n=78
Adherence by self- 
report (straightforward),  
6–9 months
Depressive symptoms (iDD)
experience of general (stressful) life events (LeS)
HIV-specific (stressful) life events (BHLES)
Neuroticism: personality style indicative of affective instability 
(NSePQSS)
ei
eii
eii
D
NS
NS
NS
NS
NR U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
0 of 6
Perceived stress (PSS)
Self-esteem (RSeQR)
eii
D
OR =0.88 (0.77, 0.98), P=0.04
NS
U: − 
M: NR
U: 0 
M: NR
Godin14 Canada; patients from medical  
Hiv-clinics, n=400
Adherence over  
time by self-report  
(straightforward),  
12 months
Change in predictors related to adherence over time: attitude 
towards medication-taking (more positive attitude = greater 
adherence, self-developed scale)
Optimism (DOS)
Outcome expectations (eg, believe that specific course of 
action will lead to desired outcome, self-developed scale)
Patient-doctor satisfaction (Pat SS)
Self-efficacy regarding medication taking (self-developed scale)
Social support (SPS)
Ai
D
Aiii
Ci
Aiii
Ciii
NR OR =1.56 (1.18, 2.06), P#0.05
NS
NS
NS
OR =1.68 (1.27, 2.22), P#0.05
NS
U: NR 
M: +
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: +
U: NR 
M: 0
1 of 6
Kacanek15 USA; patients recruited by media  
and physician networks, n=225
Suboptimal adherence  
by self-report  
(straightforward):  
max 30 months
Development of depressive symptoms (BST) ei Suboptimal adherence in those who  
developed depressive symptoms =45.1%  
versus 25.9% in those with no  
depressive symptoms, P=0.01
NT U: − 
M: NT
2 of 6
Martini16,§§§ italy; outpatients using combination  
therapy, n=214
Adherence by self- 
report (ordinal measure,  
straightforward  
questionnaire),  
12 months
(interview, instrument NR): perception of therapy: reliable?
Perception of therapy: enslaving?
Satisfied about doctor/patient discussion regarding clinical and 
therapeutic aspects of treatment?
Ai
Ai
Ci
in “high adherence” category, therapy  
perceived as “reliable” by 15.6%, and “not reliable”  
by 84.4%. in “variable adherence” cat 4.8% versus 
95.2%. in “low adherence” cat 0% versus  
100%, P=0.02
NS
in “high adherence” category:  
“sufficient/highly satisfied” = 73.9%,  
“little/not satisfied” =26.1%. in “variable  
adherence” cat 80% versus 20%. in  
“low adherence” cat 50% versus 50%, P=0.05
NR U: + 
M: NR
U: 0 
M: NR
U: ? 
M: NR
0 of 6
Mellins17 USA; Hiv-infected mothers  
recruited in waiting room  
of adult clinic, n=128
Non-adherence by  
self-report (AACTG,  
straightforward),  
T1 after 4–5 months,  
T2 8–18 months after T1
Negative stressful events (Pei)
Parenting stress (low scores = more stress, PPCS)
Psychological distress (aggregated demoralization score, 
DSPeRi)
Self-efficacy in carrying out health-related behaviors  
(Chesney et al34)
eii
eii
ei
Aiii
OR =1.27 (1.09, 1.49), P,0.01 at T1,  
OR =1.28 (1.05, 1.57), P=0.02 at T2
OR =0.86 (0.76, 0.98), P=0.02 at T2
NS
NS
NR U: − 
M: NR
U: − 
M: NR
U: 0 
M: NR
U: 0 
M: NR
0 of 6
(Continued)
Patient Preference and Adherence 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
552
Zwikker et al
Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Nilsson  
Schönnesson18
Sweden; patients recruited by  
clinic nurses, n=203
Adherence by self-report  
(straightforward),  
24 months
Anxiety symptoms (ASBSi)
Belief in adherence necessity (one item)
Belief that ART prolongs one’s life (one item)
Belief in future Hiv-related health problems (self-developed 
scale)
Belief in influencing HIV disease (MAH)
Beliefs in ART health concerns (eg, believe that medication 
makes sicker, one item)
Coping mode: helplessness (MAH)
ei
Ai
Ai
Aii
Aiii
Ai
Bii
NR NS
NS
NS
NS
NS
NS
NS
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
1 of 6
Coping mode: resilience (MAH)
Depressive symptoms (DSBSi)
Global social support satisfaction (one item)
Hopelessness (BHS)
Life stress (LSS)
Patient-provider relationship (self-developed scale)
Perceived pressure to take Hiv medication (self-developed 
scale)
Posttraumatic stress disorder symptoms related to Hiv 
diagnosis (Hie)
Self-efficacy in taking medication (self-developed scale)
D
ei
Ciii
Bii
eii
Ci
Ciii
ei
Aiii
NS
NS
NS
NS
NS
NS
NS
NS
NS
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
Thrasher19 USA; patients in public use  
of HCSUS data-set, n=1,911
Adherence by self-report  
(straightforward),  
12 months
(instruments NR): depressive symptoms
Dysthymia symptoms
Social support
ei
ei
Ciii
OR =0.98 (0.96, 0.99), P=0.007
OR =0.92 (0.87, 0.96), P=0.001
NS
NR U: − 
M: NR
U: − 
M: NR
U: 0 
M: NR
1 of 6
Horne20 UK; outpatients, eligible to receive  
HAART, n=136
Adherence by self- 
report (vAS-scale from  
MASRi, straightforward),  
12 months
Depressive symptoms (HADS)
HAART concern beliefs about medication (BMQ)
HAART necessity beliefs about medication
ei
Ai
Ai
NS
High adherence 2.9 (0.6) versus low  
adherence 3.3 (0.6), P=0.005
High adherence 4.0 (0.6) versus low  
adherence 3.7 (0.6), P=0.006
NT
OR =0.45 (0.22, 0.96), P=0.038
OR =2.19 (1.02, 4.71), P=0.045
U: 0 
M: NT
U: − 
M: −
U: + 
M: +
3 of 6
Mugavero21 USA; patients receiving care at one  
of eight infectious disease clinics,  
n=474
Non-adherence by  
self-report (AACTG,  
straightforward,  
corrected for baseline  
non-adherence),  
27 months
Number of severe stressful events (LES, modified version)
Number of stressful events (moderate + severe stressful events)
Number of traumatic events
Number of types of lifetime traumatic experiences (composite 
measure of diverse questionnaires)
eii
eii
eii
eii
OR (per event) =1.14 (1.03, 1.26)
OR (per event) =1.09 (1.04, 1.13)
OR (per event) =1.73 (1.24, 2.39)
NS
NS
OR (per event) =1.10 (1.04, 1.16)
NS
NS
U: − 
M: 0
U: − 
M: −
U: − 
M: 0
U: 0 
M: 0
3 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Nilsson  
Schönnesson18
Sweden; patients recruited by  
clinic nurses, n=203
Adherence by self-report  
(straightforward),  
24 months
Anxiety symptoms (ASBSi)
Belief in adherence necessity (one item)
Belief that ART prolongs one’s life (one item)
Belief in future Hiv-related health problems (self-developed 
scale)
Belief in influencing HIV disease (MAH)
Beliefs in ART health concerns (eg, believe that medication 
makes sicker, one item)
Coping mode: helplessness (MAH)
ei
Ai
Ai
Aii
Aiii
Ai
Bii
NR NS
NS
NS
NS
NS
NS
NS
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
1 of 6
Coping mode: resilience (MAH)
Depressive symptoms (DSBSi)
Global social support satisfaction (one item)
Hopelessness (BHS)
Life stress (LSS)
Patient-provider relationship (self-developed scale)
Perceived pressure to take Hiv medication (self-developed 
scale)
Posttraumatic stress disorder symptoms related to Hiv 
diagnosis (Hie)
Self-efficacy in taking medication (self-developed scale)
D
ei
Ciii
Bii
eii
Ci
Ciii
ei
Aiii
NS
NS
NS
NS
NS
NS
NS
NS
NS
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
Thrasher19 USA; patients in public use  
of HCSUS data-set, n=1,911
Adherence by self-report  
(straightforward),  
12 months
(instruments NR): depressive symptoms
Dysthymia symptoms
Social support
ei
ei
Ciii
OR =0.98 (0.96, 0.99), P=0.007
OR =0.92 (0.87, 0.96), P=0.001
NS
NR U: − 
M: NR
U: − 
M: NR
U: 0 
M: NR
1 of 6
Horne20 UK; outpatients, eligible to receive  
HAART, n=136
Adherence by self- 
report (vAS-scale from  
MASRi, straightforward),  
12 months
Depressive symptoms (HADS)
HAART concern beliefs about medication (BMQ)
HAART necessity beliefs about medication
ei
Ai
Ai
NS
High adherence 2.9 (0.6) versus low  
adherence 3.3 (0.6), P=0.005
High adherence 4.0 (0.6) versus low  
adherence 3.7 (0.6), P=0.006
NT
OR =0.45 (0.22, 0.96), P=0.038
OR =2.19 (1.02, 4.71), P=0.045
U: 0 
M: NT
U: − 
M: −
U: + 
M: +
3 of 6
Mugavero21 USA; patients receiving care at one  
of eight infectious disease clinics,  
n=474
Non-adherence by  
self-report (AACTG,  
straightforward,  
corrected for baseline  
non-adherence),  
27 months
Number of severe stressful events (LES, modified version)
Number of stressful events (moderate + severe stressful events)
Number of traumatic events
Number of types of lifetime traumatic experiences (composite 
measure of diverse questionnaires)
eii
eii
eii
eii
OR (per event) =1.14 (1.03, 1.26)
OR (per event) =1.09 (1.04, 1.13)
OR (per event) =1.73 (1.24, 2.39)
NS
NS
OR (per event) =1.10 (1.04, 1.16)
NS
NS
U: − 
M: 0
U: − 
M: −
U: − 
M: 0
U: 0 
M: 0
3 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Carrieri22 France; patients starting HAART- 
regimen including at least one  
protease inhibitor, n=1,110
Non-adherence by  
self-report (AACTG,  
straightforward),  
60 months
Depressive symptoms (CeS-D)
Support from partner (whether principal or not, instrument 
NR)
ei
Cii
b =0.22 (95% Ci =0.12, 0.32), P,0.001
b =−0.16 (−0.26, −0.07), P=0.001
b =0.18 (0.07, 0.29)
b =−0.15 (−0.25, −0.05)
U: − 
M: −
U: + 
M: +
2 of 6
Transplant-related (immunosuppressant medication)
Stilley23 USA; transplant patients, recruited  
before hospital discharge or at  
early clinic visit, n=152
Adherence by MeMS  
(continuous measure),  
6 months
Affective dysregulation (degree of negative affectivity and 
irritability, Di)
Behavioral dysregulation (impulsivity, sensation seeking, 
aggression)
Cognitive dysregulation (less strategic thinking, problem 
solving, self-monitoring)
Family environment (family support, FRi)
Hostility (CMHS)
ei
D
Bi
Cii
D
Correlation coefficient: NS¶¶
r=0.26, P#0.05***
NS¶¶
NS¶¶
NS¶¶
NR U: 0 
M: NR
U: −††† 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
1 of 6
De Geest24 Belgium; convenience sample  
of outpatients, n=101
Non-adherence by  
MeMS (ordinal measure,  
correction for past  
adherence), 6 months
Depressive symptoms (BDi)
Self-efficacy in taking medication (LTMSES)
Social support (PRQ)
Symptom distress (ATSFDS)
ei
Aiii
Ciii
eii
NR NS
Median =4.85 (Q1 =4.70,  
Q3 =5.00) for excellent adherers, 
4.81 (Q1 =4.70, Q3 =4.89) for  
moderate non-adherers,  
4.41 (Q1 =4.30, Q3 =4.81) for 
minor adherers, P=0.04
NS
NS
U: NR 
M: 0
U: NR 
M: +
U: NR 
M: 0
U: NR 
M: 0
2 of 6
Russell25 USA; convenience sample of renal  
transplant patients, n=50
Adherence by MeMS  
(ordinal measure),  
12 months
Depressive symptoms (BDi)
emotional burden (MS)
Self-efficacy in taking medication (LTMSES)
Social support (SSAi)
ei
ei
Aiii
Ciii
NS
NS
NS
NS
NR U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
0 of 6
weng26 USA; patients recruited at time  
of renal transplantation, n=829
Adherence by MeMS  
(ordinal measure),  
12 months post- 
transplantation
Beliefs regarding who or what controls and influences one’s 
health (MHLCS)
Depressive symptoms (CeS-D)
Perceived stressfulness of transplant-related issues (TSQ)
Perceptions that social needs are being met (friends and family 
sub-score, SSAS)
Aiii
ei
eii
Cii
OR =1.05 (1.00, 1.11), P=0.05 (powerful others 
subscale)
NS
NS
NS
NS
NT
NT
NT
U: + 
M: 0
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
2 of 6
Dew27 USA; heart transplant patients  
at academic hospital‡‡‡, n=108
Non-adherence by  
self-report (straight-  
forward), 12 months  
post-transplantation
Coping strategies: use of active-behavioral coping  
(Coping checklist)
Coping strategies: use of active-cognitive coping
Coping strategies: use of avoidance coping (% high)
emotional status: anger-hostility symptoms (SCL-90)
emotional status: anxiety symptoms
emotional status: depressive symptoms
Bi
Bi
Bii
ei
ei
ei
NS
NS
Non-adherent 58.8%, adherent 29.9%, P,0.05
Non-adherent 47.1%, adherent 12.1%, P,0.001
Non-adherent 82.4%, adherent 53%, P,0.05
NS
NT
NT
OR =9.71, P,0.05
OR =13.40, P,0.05
NS
NT
U: 0 
M: NT
U: 0 
M: NT
U: − 
M: −
U: − 
M: −
U: − 
M: 0
U: 0 
M: NT
2 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Carrieri22 France; patients starting HAART- 
regimen including at least one  
protease inhibitor, n=1,110
Non-adherence by  
self-report (AACTG,  
straightforward),  
60 months
Depressive symptoms (CeS-D)
Support from partner (whether principal or not, instrument 
NR)
ei
Cii
b =0.22 (95% Ci =0.12, 0.32), P,0.001
b =−0.16 (−0.26, −0.07), P=0.001
b =0.18 (0.07, 0.29)
b =−0.15 (−0.25, −0.05)
U: − 
M: −
U: + 
M: +
2 of 6
Transplant-related (immunosuppressant medication)
Stilley23 USA; transplant patients, recruited  
before hospital discharge or at  
early clinic visit, n=152
Adherence by MeMS  
(continuous measure),  
6 months
Affective dysregulation (degree of negative affectivity and 
irritability, Di)
Behavioral dysregulation (impulsivity, sensation seeking, 
aggression)
Cognitive dysregulation (less strategic thinking, problem 
solving, self-monitoring)
Family environment (family support, FRi)
Hostility (CMHS)
ei
D
Bi
Cii
D
Correlation coefficient: NS¶¶
r=0.26, P#0.05***
NS¶¶
NS¶¶
NS¶¶
NR U: 0 
M: NR
U: −††† 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
1 of 6
De Geest24 Belgium; convenience sample  
of outpatients, n=101
Non-adherence by  
MeMS (ordinal measure,  
correction for past  
adherence), 6 months
Depressive symptoms (BDi)
Self-efficacy in taking medication (LTMSES)
Social support (PRQ)
Symptom distress (ATSFDS)
ei
Aiii
Ciii
eii
NR NS
Median =4.85 (Q1 =4.70,  
Q3 =5.00) for excellent adherers, 
4.81 (Q1 =4.70, Q3 =4.89) for  
moderate non-adherers,  
4.41 (Q1 =4.30, Q3 =4.81) for 
minor adherers, P=0.04
NS
NS
U: NR 
M: 0
U: NR 
M: +
U: NR 
M: 0
U: NR 
M: 0
2 of 6
Russell25 USA; convenience sample of renal  
transplant patients, n=50
Adherence by MeMS  
(ordinal measure),  
12 months
Depressive symptoms (BDi)
emotional burden (MS)
Self-efficacy in taking medication (LTMSES)
Social support (SSAi)
ei
ei
Aiii
Ciii
NS
NS
NS
NS
NR U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
U: 0 
M: NR
0 of 6
weng26 USA; patients recruited at time  
of renal transplantation, n=829
Adherence by MeMS  
(ordinal measure),  
12 months post- 
transplantation
Beliefs regarding who or what controls and influences one’s 
health (MHLCS)
Depressive symptoms (CeS-D)
Perceived stressfulness of transplant-related issues (TSQ)
Perceptions that social needs are being met (friends and family 
sub-score, SSAS)
Aiii
ei
eii
Cii
OR =1.05 (1.00, 1.11), P=0.05 (powerful others 
subscale)
NS
NS
NS
NS
NT
NT
NT
U: + 
M: 0
U: 0 
M: NT
U: 0 
M: NT
U: 0 
M: NT
2 of 6
Dew27 USA; heart transplant patients  
at academic hospital‡‡‡, n=108
Non-adherence by  
self-report (straight-  
forward), 12 months  
post-transplantation
Coping strategies: use of active-behavioral coping  
(Coping checklist)
Coping strategies: use of active-cognitive coping
Coping strategies: use of avoidance coping (% high)
emotional status: anger-hostility symptoms (SCL-90)
emotional status: anxiety symptoms
emotional status: depressive symptoms
Bi
Bi
Bii
ei
ei
ei
NS
NS
Non-adherent 58.8%, adherent 29.9%, P,0.05
Non-adherent 47.1%, adherent 12.1%, P,0.001
Non-adherent 82.4%, adherent 53%, P,0.05
NS
NT
NT
OR =9.71, P,0.05
OR =13.40, P,0.05
NS
NT
U: 0 
M: NT
U: 0 
M: NT
U: − 
M: −
U: − 
M: −
U: − 
M: 0
U: 0 
M: NT
2 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Sense of mastery (ie, control over life, SMS)
Social support: caregiver support (% poor) (Spanier,35 Pearlin 
and Schooler)36
Social support: friend support (Moos)37
Aiii
Cii
Cii
NS
Non-adherent 52.9%, adherent 27.0%, P,0.05
NS
NT
NS
NT
U: 0 
M: NT
U: − 
M: 0
U: 0 
M: NT
Dew28 USA; patients receiving first lung  
transplantation in academic hospital,  
n=178
Non-adherence by self- 
report (straightforward),  
24 months
Anger-hostility symptoms (SC)
Anxiety symptoms (SC)
Care provider locus of control (health outcomes due to 
professional? MHLCS)
Chance locus of control (health outcomes occur by  
chance?)
Degree to which one can rely on friends for emotional/
practical support/friend support (Moos)37
ei
ei
Aiii
Aiii
Cii
(Correlation coefficient, significant if  
r$0.15***): r$0.15
r$0.15
r$0.15
r$0.15
r$0.15
NS
NS
NS
NS
NS
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: 0
1 of 6
Depressive symptoms (SC)
expectations about the future/optimism (LOT)
Internal locus of control (can I influence my health outcome? 
MHLCS)
Supportiveness (both emotionally and practically) of 
recipient’s relationship with their primary family caregiver 
(when low = higher odds) (DAS)
ei
D
Aiii
Cii
r$0.15
r$0.15
r$0.15
r$0.15
NS
NS
NS
OR =2.59 (1.20, 5.58), P,0.05
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: −
Dobbels29 Belgium: heart, liver and lung  
transplant patients listed at  
university hospitals, n=186
Non-adherence by self- 
report (straightforward,  
corrected for pre- 
transplant adherence),  
12 months post- 
transplantation
Agreeableness (one’s orientation along continuum from 
compassion to antagonism, NeO-FFi)
Anxiety symptoms (HADS)
Conscientiousness (ie, degree of organization, NeO-FFi)
Depressive symptoms (HADS)
extraversion (capacity for joy, need for stimulation,  
NeO-FFi)
General received practical and informational support (SSQ)
Neuroticism (NeO-FFi)
Openness to experience (toleration for and exploration of the 
unfamiliar, NeO-FFi)
Received specific support with medication taking (SSQ)
D
ei
D
ei
D
Ciii
D
D
Ciii
NR NT or NS
NT or NS
OR =0.80 (0.67, 0.95), P=0.01
NT or NS
NT or NS
NT or NS
NT or NS
NT or NS
OR =0.94 (0.89, 0.99), P=0.03
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: +
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: +
1 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Sense of mastery (ie, control over life, SMS)
Social support: caregiver support (% poor) (Spanier,35 Pearlin 
and Schooler)36
Social support: friend support (Moos)37
Aiii
Cii
Cii
NS
Non-adherent 52.9%, adherent 27.0%, P,0.05
NS
NT
NS
NT
U: 0 
M: NT
U: − 
M: 0
U: 0 
M: NT
Dew28 USA; patients receiving first lung  
transplantation in academic hospital,  
n=178
Non-adherence by self- 
report (straightforward),  
24 months
Anger-hostility symptoms (SC)
Anxiety symptoms (SC)
Care provider locus of control (health outcomes due to 
professional? MHLCS)
Chance locus of control (health outcomes occur by  
chance?)
Degree to which one can rely on friends for emotional/
practical support/friend support (Moos)37
ei
ei
Aiii
Aiii
Cii
(Correlation coefficient, significant if  
r$0.15***): r$0.15
r$0.15
r$0.15
r$0.15
r$0.15
NS
NS
NS
NS
NS
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: 0
1 of 6
Depressive symptoms (SC)
expectations about the future/optimism (LOT)
Internal locus of control (can I influence my health outcome? 
MHLCS)
Supportiveness (both emotionally and practically) of 
recipient’s relationship with their primary family caregiver 
(when low = higher odds) (DAS)
ei
D
Aiii
Cii
r$0.15
r$0.15
r$0.15
r$0.15
NS
NS
NS
OR =2.59 (1.20, 5.58), P,0.05
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: 0
U: ? 
M: −
Dobbels29 Belgium: heart, liver and lung  
transplant patients listed at  
university hospitals, n=186
Non-adherence by self- 
report (straightforward,  
corrected for pre- 
transplant adherence),  
12 months post- 
transplantation
Agreeableness (one’s orientation along continuum from 
compassion to antagonism, NeO-FFi)
Anxiety symptoms (HADS)
Conscientiousness (ie, degree of organization, NeO-FFi)
Depressive symptoms (HADS)
extraversion (capacity for joy, need for stimulation,  
NeO-FFi)
General received practical and informational support (SSQ)
Neuroticism (NeO-FFi)
Openness to experience (toleration for and exploration of the 
unfamiliar, NeO-FFi)
Received specific support with medication taking (SSQ)
D
ei
D
ei
D
Ciii
D
D
Ciii
NR NT or NS
NT or NS
OR =0.80 (0.67, 0.95), P=0.01
NT or NS
NT or NS
NT or NS
NT or NS
NT or NS
OR =0.94 (0.89, 0.99), P=0.03
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: +
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: 0
U: NR/NS 
M: +
1 of 6
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Other (diabetes and/or hypertension and/or heart disease)
DiMatteo30,|| || USA: patients from five medical  
specialties in HMOs, large  
multispecialty groups or solo  
practices, n=max 1,828§§§
Adherence by self- 
report (straightforward,  
continuous measure,  
correction for baseline  
adherence), 24 months
Health distress (instrument NR)
Perceptions of physician’s authoritativeness (self-developed 
scale)
Satisfaction with interpersonal medical care (Sherbourne)38
Social support (composite measure, Sherbourne and Stewart)39
Tendency to use avoidance coping (instrument NR)
eii
Ci
Ci
Ciii
Bii
NR β =−0.22, P=0.05
NT or NS
NT or NS
NT or NS
NT or NS
U: NR 
M: −
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
0 of 6
Notes: *NS (non significant): as reported in the concerning study.  UD (undetermined): because of inadequate description in the concerning study. †Binary outcome measure, unless indicated otherwise. 
with a straightforward question, we mean that participants were directly asked to indicate how many medication doses they missed. For example: “How many pills did you take this week?”; ‡follow-
up period = number of months between baseline (unless indicated otherwise) and last adherence measurement; §if no instrument is mentioned for predictor, then previous mentioned instrument is 
applicable; ||psychosocial category, to which a predictor was assigned. A = Beliefs and cognitions about: I) medication and treatment; II) illness; III) self-efficacy and locus of control. B = coping styles: i) 
task oriented, ii) emotion oriented. C = Social influences and social support: I) regarding medical caregiver; II) regarding friends and family; III) in general. D = personality traits. e = psychological well-
being: i) mood state; ii) perceived stress/stressors; ¶OR: Odds Ratio (95% confidence interval). OR ,1 = lower chance of being adherent or non-adherent (for direction in relevant study, see column 
“Adherence, follow-up period”) when predictor increases or when predictor ≠ reference category. OR .1 = greater change of being adherent or non-adherent when predictor increases (or when 
predictor ≠ reference category). Scores other than OR are the mean predictor scores with standard deviation, unless indicated otherwise; **+ = higher level of predictor implies higher adherence at 
level P#0.05; − = higher level of predictor implies less adherence at P#0.05; 0 = no significant association between predictor and adherence at P#0.05; ? = association present, but direction unclear; ††to 
determine methodological quality, six bias domains per study were judged. Here, the total amount of bias free domains is reported (for further details, see table S3); ‡‡assumed that all variables, tested 
by univariate analysis, were also tested by multivariate analysis; §§retrospective design; || ||Diagnosis for coronary heart disease, hypertension, diabetes mellitus and/or hyperlipidaemia; ¶¶not reported in 
study is interpreted by HZ/BvdB as not significant; ***significance of P#0.05 assumed by HZ/BvdB; †††negative association assumed; ‡‡‡type of medication is immunosuppressants, antihypertensives, and/
or antivirals; §§§use of chronic preventive medication assumed; || || ||unexpected direction.
Abbreviations: AACTG, adult AIDS clinical trials group; ALTMBSES, adapted long term medication behavior self efficacy scale; AGSRP, adapted gay service research project; AIDS, acquired 
immunodeficiency syndrome; AMHI, adapted mental health inventory; APIAQ, adapted protease inhibitor attitude questionnaire; ART, antiretroviral therapy; ASBSI, anxiety subscale of brief symptom 
inventory; ATS, anxiety trait scale; ATSFDS, adapted version of transplant symptom frequency and distress scale; AwC, adapted ways of coping; BDi, beck depression inventory; BHLeS, buffalo Hiv life 
events survey; BHS, beck hopelessness scale; BMiCiS, Billings and Moos inventory of coping with illness styles; BMQ, beliefs about medication questionnaire; BST, Burnam interviewer-administered 8-item 
screening tool; CeS-D, center for epidemiologic studies depression scale; CMHS, Cook-Medley hostility scale; DAS, dyadic adjustment scale; Di, dysregulation inventory; DOS, dispositional optimism 
scale; DSBSi, depression subscale of brief symptom inventory; DSPeRi, demoralization scale of psychiatric epidemiology research interview; FRi, family relations index (from family environment scale); 
FTSSH, Finnish twin study scale of hostility; GHQ, general health questionnaire; HAART, highly active antiretroviral therapy; HADS, hospital anxiety and depression scale; HAT-QOL, Hiv/AiDS-targeted 
quality of life instrument; HBS, health behaviour scale; HCSUS, HIV cost and services utilization study; HIE, Horowitz impact of events scale; HIS, health intention scale; HIV, human immunodeficiency 
virus; HMO, health maintenance organization; iCS, inhaled corticosteroids; iDD, inventory to diagnose depression; iQR, interquartile range; iSeL, interpersonal support evaluation list; LeS, life experience 
survey; LOT-R, life orientation test; LSS, life stressors scale; LTMSES, long term medication self-efficacy scale; MAH, mental adjustment to HIV; MARS, medication adherence report scale; MAS, Miller 
attitude scale; MASRi, medication adherence self-report inventory; MeMS, medication even monitoring system; MHLCS, multidimensional health locus of control scale; MOS, medical outcome study 
health survey; MS, Memphis survey; NEO-FFI, NEO five factor inventory; NR, not reported; NS, non-significant; NSEPQSS, neuroticism scale of the Eysenck personality questionnaire-revised short scale; 
NT, not tested; OR, odds ratio; Pat SS, patient satisfaction scale; PEI, psychiatric epidemiology interview; POMS, profiles of mood states; PPCS, perceived parenting competence scale; PRQ, personal 
resource questionnaire; PSS, perceived stress scale; RSeQR, Rosenberg self-esteem questionnaire; SC, symptom checklist; SCL-90, Symptom Checklist-90-R; SeM, standard error of the mean; SF-36, 
short form-36 health survey; SMS, sense of mastery scale; SOC, sense of coherence; SPS, social provision scale; SSAi, social support appraisals index; SSAS, social support appraisal scale; SSQ, social 
support questionnaire; TSQ, transplant stress questionnaire; vAS, visual analog scale.
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Table S2 (Continued)
First author Setting, n patients Measures Psychcat|| Results¶ Direction of association  
(regarding adherence)**
N domains 
bias free††Adherence†,  
follow-up period‡
Psychosocial predictors§ Univariate Multivariate
Other (diabetes and/or hypertension and/or heart disease)
DiMatteo30,|| || USA: patients from five medical  
specialties in HMOs, large  
multispecialty groups or solo  
practices, n=max 1,828§§§
Adherence by self- 
report (straightforward,  
continuous measure,  
correction for baseline  
adherence), 24 months
Health distress (instrument NR)
Perceptions of physician’s authoritativeness (self-developed 
scale)
Satisfaction with interpersonal medical care (Sherbourne)38
Social support (composite measure, Sherbourne and Stewart)39
Tendency to use avoidance coping (instrument NR)
eii
Ci
Ci
Ciii
Bii
NR β =−0.22, P=0.05
NT or NS
NT or NS
NT or NS
NT or NS
U: NR 
M: −
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
U: NR 
M: 0
0 of 6
Notes: *NS (non significant): as reported in the concerning study.  UD (undetermined): because of inadequate description in the concerning study. †Binary outcome measure, unless indicated otherwise. 
with a straightforward question, we mean that participants were directly asked to indicate how many medication doses they missed. For example: “How many pills did you take this week?”; ‡follow-
up period = number of months between baseline (unless indicated otherwise) and last adherence measurement; §if no instrument is mentioned for predictor, then previous mentioned instrument is 
applicable; ||psychosocial category, to which a predictor was assigned. A = Beliefs and cognitions about: I) medication and treatment; II) illness; III) self-efficacy and locus of control. B = coping styles: i) 
task oriented, ii) emotion oriented. C = Social influences and social support: I) regarding medical caregiver; II) regarding friends and family; III) in general. D = personality traits. e = psychological well-
being: i) mood state; ii) perceived stress/stressors; ¶OR: Odds Ratio (95% confidence interval). OR ,1 = lower chance of being adherent or non-adherent (for direction in relevant study, see column 
“Adherence, follow-up period”) when predictor increases or when predictor ≠ reference category. OR .1 = greater change of being adherent or non-adherent when predictor increases (or when 
predictor ≠ reference category). Scores other than OR are the mean predictor scores with standard deviation, unless indicated otherwise; **+ = higher level of predictor implies higher adherence at 
level P#0.05; − = higher level of predictor implies less adherence at P#0.05; 0 = no significant association between predictor and adherence at P#0.05; ? = association present, but direction unclear; ††to 
determine methodological quality, six bias domains per study were judged. Here, the total amount of bias free domains is reported (for further details, see table S3); ‡‡assumed that all variables, tested 
by univariate analysis, were also tested by multivariate analysis; §§retrospective design; || ||Diagnosis for coronary heart disease, hypertension, diabetes mellitus and/or hyperlipidaemia; ¶¶not reported in 
study is interpreted by HZ/BvdB as not significant; ***significance of P#0.05 assumed by HZ/BvdB; †††negative association assumed; ‡‡‡type of medication is immunosuppressants, antihypertensives, and/
or antivirals; §§§use of chronic preventive medication assumed; || || ||unexpected direction.
Abbreviations: AACTG, adult AIDS clinical trials group; ALTMBSES, adapted long term medication behavior self efficacy scale; AGSRP, adapted gay service research project; AIDS, acquired 
immunodeficiency syndrome; AMHI, adapted mental health inventory; APIAQ, adapted protease inhibitor attitude questionnaire; ART, antiretroviral therapy; ASBSI, anxiety subscale of brief symptom 
inventory; ATS, anxiety trait scale; ATSFDS, adapted version of transplant symptom frequency and distress scale; AwC, adapted ways of coping; BDi, beck depression inventory; BHLeS, buffalo Hiv life 
events survey; BHS, beck hopelessness scale; BMiCiS, Billings and Moos inventory of coping with illness styles; BMQ, beliefs about medication questionnaire; BST, Burnam interviewer-administered 8-item 
screening tool; CeS-D, center for epidemiologic studies depression scale; CMHS, Cook-Medley hostility scale; DAS, dyadic adjustment scale; Di, dysregulation inventory; DOS, dispositional optimism 
scale; DSBSi, depression subscale of brief symptom inventory; DSPeRi, demoralization scale of psychiatric epidemiology research interview; FRi, family relations index (from family environment scale); 
FTSSH, Finnish twin study scale of hostility; GHQ, general health questionnaire; HAART, highly active antiretroviral therapy; HADS, hospital anxiety and depression scale; HAT-QOL, Hiv/AiDS-targeted 
quality of life instrument; HBS, health behaviour scale; HCSUS, HIV cost and services utilization study; HIE, Horowitz impact of events scale; HIS, health intention scale; HIV, human immunodeficiency 
virus; HMO, health maintenance organization; iCS, inhaled corticosteroids; iDD, inventory to diagnose depression; iQR, interquartile range; iSeL, interpersonal support evaluation list; LeS, life experience 
survey; LOT-R, life orientation test; LSS, life stressors scale; LTMSES, long term medication self-efficacy scale; MAH, mental adjustment to HIV; MARS, medication adherence report scale; MAS, Miller 
attitude scale; MASRi, medication adherence self-report inventory; MeMS, medication even monitoring system; MHLCS, multidimensional health locus of control scale; MOS, medical outcome study 
health survey; MS, Memphis survey; NEO-FFI, NEO five factor inventory; NR, not reported; NS, non-significant; NSEPQSS, neuroticism scale of the Eysenck personality questionnaire-revised short scale; 
NT, not tested; OR, odds ratio; Pat SS, patient satisfaction scale; PEI, psychiatric epidemiology interview; POMS, profiles of mood states; PPCS, perceived parenting competence scale; PRQ, personal 
resource questionnaire; PSS, perceived stress scale; RSeQR, Rosenberg self-esteem questionnaire; SC, symptom checklist; SCL-90, Symptom Checklist-90-R; SeM, standard error of the mean; SF-36, 
short form-36 health survey; SMS, sense of mastery scale; SOC, sense of coherence; SPS, social provision scale; SSAi, social support appraisals index; SSAS, social support appraisal scale; SSQ, social 
support questionnaire; TSQ, transplant stress questionnaire; vAS, visual analog scale.
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Table S3 Results of judging methodologic quality
First author Overall  
quality
Domain free of bias?
Study  
participation
Study  
attrition
Prognostic factor  
measurement
Outcome  
measurement
Confounding measurement  
and account
Analysis
Bottonari13 Low No No Partly Partly No No
De Geest24 Low No Yes Partly Yes No Partly
Delgado10 Low Partly Yes Partly Partly Partly Partly
Deschamps8 Low No Partly No Yes No No
Dew27 Low No Yes Yes Partly Partly Partly
Dew28 Low Yes Partly Partly Partly Partly Partly
DiMatteo30 Low Partly No Partly No No No
Dobbels29 Low Yes Partly Partly Partly Partly No
Gazmararian3 Low Yes Partly Partly Yes Partly Yes
Godin14 Low Partly Yes No Partly Partly Partly
Grégoire5 Low Partly No No Partly No Partly
Holmes9 Low Partly Yes Partly Partly Partly Yes
Kacanek15 Low No Yes Partly Partly No Yes
Martini16 Low Partly No No Partly No No
Mellins17 Low Partly Partly Partly No No No
Miller6 Low No Partly Partly No Partly Partly
Nabi4 Low Partly Partly Partly Partly Partly Yes
Nilsson  
Schönnesson18
Low Partly Yes Partly No Partly No
Ponieman1 Low No No Partly Partly Partly Partly
Russell25 Low No No Partly Partly No Partly
Singh11 Low No Yes Partly Partly Partly No
Singh12 Low Partly Yes Partly Partly No No
Stilley23 Low Yes Partly Partly No No No
Thrasher19 Low Yes Partly Partly Partly Partly Partly
venturini2 Low Yes Partly Partly Yes Partly Partly
weng26 Low Partly No Yes Partly Partly Yes
Molloy7 Low No Yes Partly No Partly Partly
Horne20 Low Yes Yes Partly Partly No Yes
Mugavero21 Low Yes No Yes Partly Partly Yes
Carrieri22 Low No Yes No Partly Partly Yes
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